HAWK: Efficacy and Safety of RTH258 Versus Aflibercept - Study 1

• Sponsor: Alcon Research (Industry)
• Overall Status: Completed
• CT.gov ID: NCT02307682
• Collaborator: (none)
• Enrollment: 1,775
• Location: 1
• Arms: 3
• Actual Duration (Months): 39.6
• Patients Per Site Per Month: 44.8

Study Details

Study Description

Brief Summary

The purpose of this study is to compare brolucizumab (RTH258) ophthalmic solution for intravitreal (IVT) injection at two dosage levels (3 mg and 6 mg) to aflibercept ophthalmic solution for IVT injection (2 mg) in subjects with untreated active choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) in the study eye.

Condition or Disease	Intervention/Treatment	Phase
Neovascular Age-Related Macular Degeneration; Choroidal Neovascularization	Drug: Brolucizumab ophthalmic solution; Drug: Aflibercept ophthalmic solution	Phase 3

Detailed Description

Subjects were randomized to brolucizumab 3 mg, brolucizumab 6 mg,and aflibercept 2 mg in a 1:1:1 ratio. Subjects in all treatment arms received 3 monthly loading doses (Day 0, Week 4 and Week 8), followed by a maintenance regimen, until the end of the study (Week 96/Exit). All subjects attended pre-specified visits every 4 weeks.

Subjects in the brolucizumab 3 mg and brolucizumab 6 mg arms followed a q12w/q8w maintenance regimen. Within the q12w/q8w regimen, the initial treatment after the loading phase was q12w (1 injection every 12 weeks). If disease activity was identified by the masked investigator at any of the disease activity assessments, dosing was adjusted to q8w (1 injection every 8 weeks) ("q12w/q8w regimen"). Once subjects were adjusted to the q8w interval, they stayed on that interval until the end of the study.

Subjects in the aflibercept 2 mg arm followed a q8w maintenance regimen until the end of the study.

Results reported up to Week 48 are based on the database locked for the primary analysis at Week 48. Results reported after Week 48 are based on the database locked at the end of study (final analysis).

Study Design

• Study Type: Interventional
• Actual Enrollment: 1775 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Double (Participant, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A Two-Year, Randomized, Double-Masked, Multicenter, Three-Arm Study Comparing the Efficacy and Safety of RTH258 Versus Aflibercept in Subjects With Neovascular Age-Related Macular Degeneration
• Actual Study Start Date: Dec 8, 2014
• Actual Primary Completion Date: Apr 22, 2017
• Actual Study Completion Date: Mar 28, 2018

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Brolucizumab 3 mg Single intravitreal (IVT) injection of brolucizumab ophthalmic solution administered as a 3 mg/50 microliter (μL) dose at Day 0, Week 4, and Week 8, followed by 1 injection every 8 weeks/1 injection every 12 weeks (q8w/q12w) maintenance regimen until study exit	Drug: Brolucizumab ophthalmic solution; Ophthalmic solution for IVT injection; Other Names: RTH258
Experimental: Brolucizumab 6 mg Single IVT injection of brolucizumab ophthalmic solution administered as a 6 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Drug: Brolucizumab ophthalmic solution; Ophthalmic solution for IVT injection; Other Names: RTH258
Active Comparator: Aflibercept 2 mg Single IVT injection of aflibercept ophthalmic solution administered as a 2 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit	Drug: Aflibercept ophthalmic solution; Ophthalmic solution for IVT injection; Other Names: EYLEA®

Outcome Measures

Primary Outcome Measures

1. Change From Baseline in Best Corrected Visual Acuity (BCVA) (Letters Read) at Week 48 - Study Eye [Baseline, Week 48]

   BCVA (with spectacles or other visual corrective devices) was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) testing at 4 meters and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. One eye (study eye) contributed to the analysis.

Secondary Outcome Measures

1. Average Change From Baseline in BCVA (Letters Read) Over the Period Week 36 Through Week 48 - Study Eye [Baseline, Weeks 36, 40, 44, 48]

   BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly. For each subject, this endpoint was defined as the average of the changes from baseline to Weeks 36, 40, 44, and 48. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. One eye (study eye) contributed to the analysis.

2. Proportion of Subjects With Positive q12 (Every 12 Weeks) Treatment Status at Week 48 [Weeks 16, 20, 28, 32, 40, 44, 48]

   Positive q12 treatment status was defined as IVT injections per planned dosing regimen (one injection every 12 weeks "q12w", after the initial three loading injections every 4 weeks "q4w"). A disease activity assessment (DAA) was performed at pre-specified visits (Weeks 16, 20, 28, 32, 40, 44) to identify q8w (one injection every 8 weeks) need. The estimate for the proportion of subjects with a positive q12w status at Week 48 were derived from Kaplan-Meier time to event analyses for the event of first q8w need, applying event allocations (in case of lack of efficacy and/or lack of safety=efficacy/safety approach) and censoring as described in the SAP. Censored subjects were considered to be not anymore under risk for a q8 need identification at later visits. Corresponding 95% Confidence Intervals (CIs) were derived from the LOGLOG transformation. No hypothesis testing was performed. This outcome measure was pre-specified for brolucizumab 3mg and 6 mg arms only.

3. Proportion of Subjects With Positive q12 Treatment Status at Week 48 Within the Subjects With no q8 (Every 8 Weeks) Treatment Need During the First q12 Cycle (Week 16, Week 20) [Weeks 16, 20, 28, 32, 40, 44, 48]

   Positive q12 treatment status was defined as IVT injections per planned dosing regimen (one injection every 12 weeks "q12w", after the initial three loading injections every 4 weeks "q4w"). A DAA was performed at pre-specified visits (Weeks 16, 20, 28, 32, 40, 44) to identify q8w need. The estimate for the proportion of subjects with a positive q12w status at Week 48 were derived from Kaplan-Meier time to event analyses for the event of first q8w need, applying event allocations (in case of lack of efficacy and/or lack of safety=efficacy/safety approach) and censoring as described in the SAP. Censored subjects were considered to be not anymore under risk for a q8 need identification at later visits. Corresponding 95% CIs were derived from the LOGLOG transformation. No hypothesis testing was performed. This outcome measure was pre-specified for the brolucizumab 3 mg and 6 mg arms only.

4. Proportion of Subjects With Positive q12 Treatment Status up to Week 96 [Weeks 16, 20, 28, 32, 40, 44, 52, 56, 64, 68, 76, 80, 88, 92, 96]

   Positive q12 treatment status was defined as IVT injections per planned dosing regimen (one injection every 12 weeks "q12w", after the initial three loading injections every 4 weeks "q4w"). A DAA was performed at pre-specified visits (Weeks 16, 20, 28, 32, 40, 44, 52, 56, 64, 68, 76, 80, 88, 92) to identify q8w need. The estimate for the proportion of subjects with a positive q12w status at Week 48 were derived from Kaplan-Meier time to event analyses for the event of first q8w need, applying event allocations (in case of lack of efficacy and/or lack of safety=efficacy/safety approach) and censoring as described in the SAP. Censored subjects were considered to be not anymore under risk for a q8 need identification at later visits. Corresponding 95% CIs were derived from the LOGLOG transformation. No hypothesis testing was performed. This outcome measure was pre-specified for the brolucizumab 3 mg and 6 mg arms only.

5. Proportion of Subjects With Positive q12 Treatment Status at Week 96 Within the Subjects With no q8 Treatment Need During the Initial q12 Cycle (Week 16, Week 20) [Weeks 16, 20, 28, 32, 40, 44, 52, 56, 64, 68, 76, 80, 88, 92, 96]

   Positive q12 treatment status was defined as IVT injections per planned dosing regimen (one injection every 12 weeks "q12w", after the initial three loading injections every 4 weeks "q4w"). A DAA was performed at pre-specified visits (Weeks 16, 20, 28, 32, 40, 44, 52, 56, 64, 68, 76, 80, 88, 92) to identify q8w need. The estimate for the proportion of subjects with a positive q12w status at Week 48 were derived from Kaplan-Meier time to event analyses for the event of first q8w need, applying event allocations (in case of lack of efficacy and/or lack of safety=efficacy/safety approach) and censoring as described in the SAP. Censored subjects were considered to be not anymore under risk for a q8 need identification at later visits. Corresponding 95% CIs were derived from the LOGLOG transformation. No hypothesis testing was performed. This outcome measure was pre-specified for the brolucizumab 3 mg and 6 mg arms only.

6. Change From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye [Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96]

   BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. One eye (study eye) contributed to the analysis.

7. Average Change From Baseline in BCVA (Letters Read) Over the Period Week 4 to Week 48/96 - Study Eye [Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96]

   BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. One eye (study eye) contributed to the analysis.

8. Average Change From Baseline in BCVA (Letters Read) Over the Period Week 12 to Week 48/96 - Study Eye [Baseline, Weeks 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96]

   BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. One eye (study eye) contributed to the analysis.

9. Average Change From Baseline in BCVA (Letters Read) Over the Period Week 84 to Week 96 - Study Eye [Baseline, Weeks 84, 88, 92, 96]

   BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. One eye (study eye) contributed to the analysis.

10. Percentage of Subjects With >=15 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye [Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96]

    BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. 95% CI for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.

11. Percentage of Subjects With >=10 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye [Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96]

    BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. 95% CI for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.

12. Percentage of Subjects With >=5 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye [Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96]

    BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. 95% CI for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.

13. Percentage of Subjects With >=15 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye [Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96]

    BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. 95% CI for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.

14. Percentage of Subjects With >=10 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye [Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96]

    BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. 95% CI for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.

15. Percentage of Subjects With >=5 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye [Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96]

    BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. 95% CI for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.

16. Percentage of Subjects With BCVA of 73 Letters Read or More at Each Visit - Study Eye [Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96]

    BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly (0-100 letters). A score of 65 to 70 letters represents a low to moderate visual acuity. Baseline was defined as the last measurement prior to first treatment. 95% CI for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.

17. Change From Baseline in Central Subfield Thickness (CSFTtot) at Each Post-baseline Visit - Study Eye [Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96]

    CSFTtot (the average retinal thickness of the circular area within 1 millimeter diameter around the foveal center) was assessed using Spectral-Domain Optical Coherence Tomography (SD-OCT), a non-invasive measurement which produces cross-sectional and 3-dimensional images of the eye. A negative change value indicates an improvement, while a positive change value indicates a worsening. One eye (study eye) contributed to the analysis.

18. Average Change From Baseline in CSFTtot Over the Period Week 36 Through Week 48 - Study Eye [Baseline, Weeks 36, 40, 44, 48]

    CSFTtot (the average retinal thickness of the circular area within 1 millimeter diameter around the foveal center) was assessed using SD-OCT, a non-invasive measurement which produces cross-sectional and 3-dimensional images of the eye. A negative change value indicates an improvement, while a positive change value indicates a worsening. One eye (study eye) contributed to the analysis.

19. Average Change From Baseline in CSFTtot Over the Period Week 84 Through Week 96 - Study Eye [Baseline, Weeks 84, 88, 92, 96]

    CSFTtot (the average retinal thickness of the circular area within 1 millimeter diameter around the foveal center) was assessed using SD-OCT, a non-invasive measurement which produces cross-sectional and 3-dimensional images of the eye. A negative change value indicates an improvement, while a positive change value indicates a worsening. One eye (study eye) contributed to the analysis.

20. Average Change From Baseline in CSFTtot Over the Period Week 4 Through Week 48/96 - Study Eye [Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96]

    CSFTtot (the average retinal thickness of the circular area within 1 millimeter diameter around the foveal center) was assessed using SD-OCT, a non-invasive measurement which produces cross-sectional and 3-dimensional images of the eye. A negative change value indicates an improvement, while a positive change value indicates a worsening. One eye (study eye) contributed to the analysis.

21. Change From Baseline in Choroidal Neovascularization (CNV) Lesion Size at Week 12, Week 48, and Week 96 - Study Eye [Baseline, Weeks 12, 48, 96]

    CNV lesion size (the area of new blood vessels in the choroid layer of the retina) size was measured using fluorescein angiography (FA). A negative change value indicates a reduction in lesion size, whereas a positive change value indicates an increase. An increase in CNV lesion size may indicate progression of the underlying disease. Only one eye (study eye) contributed to the analysis.

22. Change From Baseline in Central Subfield Neurosensory Retinal Thickness (CSFTns) at Each Post-baseline Visit - Study Eye [Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96]

    Central subfield neurosensory retinal thickness was assessed using SD-OCT. A negative change value indicates an improvement, while a positive change value indicates a worsening. One eye (study eye) contributed to the analysis.

23. Percentage of Subjects With Presence of Subretinal Fluid at Each Post-baseline Visit - Study Eye [Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96]

    Subretinal fluid was assessed using SD-OCT and recorded as Present/Absent. The presence of subretinal fluid is an indicator of underlying disease. 95% CI for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.

24. Percentage of Subjects With Presence of Intraretinal Fluid at Each Post-baseline Visit - Study Eye [Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96]

    Intraretinal fluid was assessed using SD-OCT and recorded as Present/Absent. The presence of intraretinal fluid is an indicator of underlying disease. 95% CI for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.

25. Percentage of Subjects With Presence of Sub-retinal Pigment Epithelium (RPE) Fluid at Each Post-baseline Visit - Study Eye [Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96]

    Sub-RPE fluid was assessed using SD-OCT and recorded as Present/Absent. The presence of sub-RPE fluid is an indicator of underlying disease. 95% CI for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.

26. Percentage of Subjects With Presence of Subretinal and/or Intraretinal Fluid at Each Post-baseline Visit - Study Eye [Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96]

    Subretinal fluid and intraretinal fluid were assessed using SD-OCT and recorded as Present/Absent. The presence of subretinal and/or intraretinal fluid is an indicator of underlying disease. 95% CI for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.

27. Number of Subjects With Subretinal Fluid (SRF) and/or Intraretinal Fluid (IRF) Present Between Week 36 to Week 48, Reported by Number of Visits [Weeks 36, 40, 44, 48]

    Subretinal fluid and intraretinal fluid were assessed using SD-OCT and recorded as Present/Absent. The presence of subretinal and/or intraretinal fluid is an indicator of underlying disease. One eye (study eye) contributed to the analysis. For each subject, the number of visits with SRF and/or IRF fluid is analyzed.

28. Percentage of Subjects With Disease Activity Present (q8 Treatment Need = "Yes") at Week 16 - Study Eye [Week 16]

    A disease activity assessment (DAA) was performed to identify q8 treatment need. 95% CI for binomial proportions is based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.

29. Change From Baseline in Visual Function Questionnaire (VFQ-25) Composite Score at Week 24, Week 48, Week 72, and Week 96 [Baseline, Weeks 24, 48, 72, 96]

    The National Eye Institute Visual Function Questionnaire-25 (VFQ-25) is a validated questionnaire that collects 25 vision-targeted responses from age-related macular degeneration (AMD) subjects. The 25 questions pertain to global vision rating (1), difficulty with near vision activities (3), difficulty with distance vision activities (3), limitations in social functioning due to vision (2), role limitations due to vision (2), dependency on others due to vision (3), mental health symptoms due to vision (4), driving difficulties (3), limitations with peripheral (1) and color vision (1), and ocular pain (2). Each response is converted to a 0 to 100 sub-scale, with the lowest and highest possible scores set at 0 and 100 points, respectively. The overall composite score (0 to 100) is obtained by averaging the 25 sub-scale scores. A high score represents better functioning.

30. Percentage of Subjects With Induced or Boosted Anti-drug Antibody (ADA) Status at Week 48 (Brolucizumab Only) [Week 48]

    Serum samples were collected and assessed for anti-drug antibody status. Subjects were categorized as ADA negative when one of the following was met: ADA negative at all time points (predose and postdose); ADA negative at predose and no titer values above 10 at all other time points; or ADA titer of 10 at predose but negative at all other time points. ADA induced was defined as ADA negative at predose with postdose titer value greater than or equal to a titer of 30 at any timepoint. ADA boosted was defined as ADA positive at predose with postdose titer values that increased by at least two dilutions (9-fold) from their respective predose value at any time point. Hypothesis testing not pre-specified.

31. Percentage of Subjects With Intraretinal Hemorrhage (Central Subfield) Present at the Visit While Absent at Baseline at Each Treatment - Study Eye [Baseline, Weeks 12, 48, 96]

    Intraretinal hemorrhage was assessed using SD-OCT and recorded as Present/Absent. The presence of intraretinal hemorrhage is an indicator of underlying disease. 95% CI for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis. Hypothesis testing not pre-specified.

32. Percentage of Subjects With Subretinal Hemorrhage (Central Subfield) Present at the Visit While Absent at Baseline at Each Treatment - Study Eye [Baseline, Weeks 12, 48, 96]

    Subretinal hemorrhage was assessed using SD-OCT and recorded as Present/Absent. The presence of subretinal hemorrhage is an indicator of underlying disease. 95% CI for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis. Hypothesis testing not pre-specified.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 50 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Key Inclusion Criteria:

• Provide written informed consent

• Active choroidal neovascularization (CNV) lesions secondary to age-related macular degeneration (AMD) that affected the central subfield in the study eye at Screening;

• Total area of CNV comprising >50% of the total lesion area in the study eye at Screening;

• Intraretinal and/or subretinal fluid affecting the central subfield of the study eye at Screening;

• Best Corrected Visual Acuity (BCVA) between 78 and 23 letters, inclusive, in the study eye at Screening and Baseline using Early Treatment Diabetic Retinopathy Study (ETDRS) testing.

Key Exclusion Criteria:

• Any active intraocular or periocular infection or active intraocular inflammation in either eye at Baseline;

• Central subfield of the study eye affected by fibrosis or geographic atrophy or total area of fibrosis >50% of the total lesion in the study eye at Screening;

• Subretinal blood affecting the foveal center point and/or >50% of the lesion of the study eye at Screening;

• Any approved or investigational treatment for neovascular age-related macular degeneration (nAMD) in the study eye at any time;

• Retinal pigment epithelial rip/tear in the study eye at Screening or Baseline or current vitreous hemorrhage or history of vitreous hemorrhage in the study eye within 4 weeks prior to Baseline;

• Pregnant or nursing women; women of child-bearing potential;

• Stroke or myocardial infarction in the 90-day period prior to Baseline.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Contact Alcon Call Center for Trial Locations	Fort Worth	Texas	United States	76134

Sponsors and Collaborators

• Alcon Research

Investigators

• Study Director: Group Trial Lead, Novartis Pharmaceuticals

Study Documents (Full-Text)

• Study Protocol - Aug 7, 2017
• Statistical Analysis Plan - Jun 12, 2017

More Information

Publications

None provided.

• Responsible Party: Alcon Research
• ClinicalTrials.gov Identifier: NCT02307682
• Other Study ID Numbers: RTH258-C001; CRTH258A2301
• First Posted: Dec 4, 2014
• Last Update Posted: Jan 13, 2020
• Last Verified: Oct 1, 2019

• Individual Participant Data (IPD) Sharing Statement: Undecided
• Plan to Share IPD: Undecided
• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by Alcon Research: AMD; CNV; IVT
• Additional relevant MeSH terms: Macular Degeneration; Wet Macular Degeneration; Choroidal Neovascularization; Neovascularization, Pathologic; Aflibercept; Pharmaceutical Solutions; Ophthalmic Solutions

Study Results

Participant Flow

Recruitment Details	Subjects were recruited from investigative sites located in Argentina, Australia, Canada, Colombia, Israel, Japan, Mexico, New Zealand, Panama, Puerto Rico, and USA.
Pre-assignment Detail	Of the 1775 subjects enrolled in the study, 693 were exited prior to randomization as screen failures. This reporting group includes all randomized subjects.

Arm/Group Title	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Arm/Group Description	Single intravitreal (IVT) injection of brolucizumab ophthalmic solution administered as a 3 mg/50 microliter (μL) dose at Day 0, Week 4, and Week 8, followed by 1 injection every 8 weeks/1 injection every 12 weeks (q8w/q12w) maintenance regimen until study exit	Single IVT injection of brolucizumab ophthalmic solution administered as a 6 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Single IVT injection of aflibercept ophthalmic solution administered as a 2 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Period Title: Overall Study
STARTED	360	361	361
Randomized and Treated	358	360	360
COMPLETED	310	304	297
NOT COMPLETED	50	57	64

Baseline Characteristics

Arm/Group Title	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg	Total
Arm/Group Description	Single intravitreal (IVT) injection of brolucizumab ophthalmic solution administered as a 3 mg/50 microliter (μL) dose at Day 0, Week 4, and Week 8, followed by 1 injection every 8 weeks/1 injection every 12 weeks (q8w/q12w) maintenance regimen until study exit	Single IVT injection of brolucizumab ophthalmic solution administered as a 6 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Single IVT injection of aflibercept ophthalmic solution administered as a 2 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit	Total of all reporting groups
Overall Participants	358	360	360	1078
Age (years) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [years]	76.7 (8.28)	76.7 (8.95)	76.2 (8.80)	76.5 (8.68)
Age, Customized (Count of Participants)
Less than 50 years	0 0%	0 0%	0 0%	0 0%
50-64 years	31 8.7%	35 9.7%	37 10.3%	103 9.6%
65-74 years	103 28.8%	103 28.6%	112 31.1%	318 29.5%
75-84 years	162 45.3%	155 43.1%	148 41.1%	465 43.1%
85 years and greater	62 17.3%	67 18.6%	63 17.5%	192 17.8%
Sex: Female, Male (Count of Participants)
Female	210 58.7%	205 56.9%	194 53.9%	609 56.5%
Male	148 41.3%	155 43.1%	166 46.1%	469 43.5%
Ethnicity (NIH/OMB) (Count of Participants)
Hispanic or Latino	32 8.9%	29 8.1%	40 11.1%	101 9.4%
Not Hispanic or Latino	323 90.2%	329 91.4%	319 88.6%	971 90.1%
Unknown or Not Reported	3 0.8%	2 0.6%	1 0.3%	6 0.6%
Race (NIH/OMB) (Count of Participants)
American Indian or Alaska Native	1 0.3%	1 0.3%	1 0.3%	3 0.3%
Asian	44 12.3%	61 16.9%	53 14.7%	158 14.7%
Native Hawaiian or Other Pacific Islander	0 0%	0 0%	0 0%	0 0%
Black or African American	1 0.3%	1 0.3%	1 0.3%	3 0.3%
White	302 84.4%	285 79.2%	287 79.7%	874 81.1%
More than one race	1 0.3%	3 0.8%	1 0.3%	5 0.5%
Unknown or Not Reported	9 2.5%	9 2.5%	17 4.7%	35 3.2%
Best Corrected Visual Acuity (BCVA) (letters read) (letters) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [letters]	61.0 (13.57)	60.8 (13.66)	60.0 (13.92)	60.6 (13.71)

Outcome Measures

1. Primary Outcome

Title	Change From Baseline in Best Corrected Visual Acuity (BCVA) (Letters Read) at Week 48 - Study Eye
Description	BCVA (with spectacles or other visual corrective devices) was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) testing at 4 meters and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. One eye (study eye) contributed to the analysis.
Time Frame	Baseline, Week 48

Outcome Measure Data

Analysis Population Description

Full Analysis Set (FAS) - Last Observation Carried Forward (LOCF)

Arm/Group Title	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Arm/Group Description	Single intravitreal (IVT) injection of brolucizumab ophthalmic solution administered as a 3 mg/50 microliter (μL) dose at Day 0, Week 4, and Week 8, followed by 1 injection every 8 weeks/1 injection every 12 weeks (q8w/q12w) maintenance regimen until study exit	Single IVT injection of brolucizumab ophthalmic solution administered as a 6 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Single IVT injection of aflibercept ophthalmic solution administered as a 2 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Measure Participants	358	360	360
Mean (Standard Deviation) [letters]	5.9 (13.49)	6.4 (14.40)	7.0 (13.16)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments
	Type of Statistical Test	Non-Inferiority
	Comments	The non-inferiority margin was 4 letters.
Statistical Test of Hypothesis	p-Value	0.0003
	Comments	1-sided p-value reported. Hypothesis tested according to the pre-specified hierarchical testing that ensures the global type I error rate at 0.05.
	Method	ANOVA
	Comments	Analyzed using ANOVA model with baseline BCVA categories, age categories, and treatment as fixed effect factors.
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-0.6
	Confidence Interval	(2-Sided) 95%; -2.5 to 1.3
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 0.98
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments
	Type of Statistical Test	Non-Inferiority
	Comments	The non-inferiority margin was 4 letters.
Statistical Test of Hypothesis	p-Value	<0.0001
	Comments	1-sided p-value reported. Hypothesis tested according to the pre-specified hierarchical testing that ensures the global type I error rate at 0.05.
	Method	ANOVA
	Comments	Analyzed using ANOVA model with baseline BCVA categories, age categories, and treatment as fixed effect factors.
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-0.2
	Confidence Interval	(2-Sided) 95%; -2.1 to 1.8
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 1.00
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

2. Secondary Outcome

Title	Average Change From Baseline in BCVA (Letters Read) Over the Period Week 36 Through Week 48 - Study Eye
Description	BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly. For each subject, this endpoint was defined as the average of the changes from baseline to Weeks 36, 40, 44, and 48. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. One eye (study eye) contributed to the analysis.
Time Frame	Baseline, Weeks 36, 40, 44, 48

Outcome Measure Data

Analysis Population Description

FAS - LOCF

Arm/Group Title	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Arm/Group Description	Single intravitreal (IVT) injection of brolucizumab ophthalmic solution administered as a 3 mg/50 microliter (μL) dose at Day 0, Week 4, and Week 8, followed by 1 injection every 8 weeks/1 injection every 12 weeks (q8w/q12w) maintenance regimen until study exit	Single IVT injection of brolucizumab ophthalmic solution administered as a 6 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Single IVT injection of aflibercept ophthalmic solution administered as a 2 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Measure Participants	358	360	360
Mean (Standard Deviation) [letters]	6.0 (13.37)	6.5 (13.85)	6.9 (12.61)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments
	Type of Statistical Test	Non-Inferiority
	Comments	The non-inferiority margin was 4 letters.
Statistical Test of Hypothesis	p-Value	0.0001
	Comments	1-sided p-value reported. Hypothesis tested according to the pre-specified hierarchical testing that ensures the global type I error rate at 0.05.
	Method	ANOVA
	Comments	Analyzed using ANOVA model with baseline BCVA categories, age categories, and treatment as fixed effect factors.
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-0.5
	Confidence Interval	(2-Sided) 95%; -2.4 to 1.3
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 0.95
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments
	Type of Statistical Test	Non-Inferiority
	Comments	The non-inferiority margin was 4 letters.
Statistical Test of Hypothesis	p-Value	<0.0001
	Comments	1-sided p-value reported. Hypothesis tested according to the pre-specified hierarchical testing that ensures the global type I error rate at 0.05.
	Method	ANOVA
	Comments	Analyzed using ANOVA model with baseline BCVA categories, age categories, and treatment as fixed effect factors.
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	0.0
	Confidence Interval	(2-Sided) 95%; -1.9 to 1.9
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 0.96
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

3. Secondary Outcome

Title	Proportion of Subjects With Positive q12 (Every 12 Weeks) Treatment Status at Week 48
Description	Positive q12 treatment status was defined as IVT injections per planned dosing regimen (one injection every 12 weeks "q12w", after the initial three loading injections every 4 weeks "q4w"). A disease activity assessment (DAA) was performed at pre-specified visits (Weeks 16, 20, 28, 32, 40, 44) to identify q8w (one injection every 8 weeks) need. The estimate for the proportion of subjects with a positive q12w status at Week 48 were derived from Kaplan-Meier time to event analyses for the event of first q8w need, applying event allocations (in case of lack of efficacy and/or lack of safety=efficacy/safety approach) and censoring as described in the SAP. Censored subjects were considered to be not anymore under risk for a q8 need identification at later visits. Corresponding 95% Confidence Intervals (CIs) were derived from the LOGLOG transformation. No hypothesis testing was performed. This outcome measure was pre-specified for brolucizumab 3mg and 6 mg arms only.
Time Frame	Weeks 16, 20, 28, 32, 40, 44, 48

Outcome Measure Data

Analysis Population Description

FAS - efficacy/safety approach

Arm/Group Title	Brolucizumab 3 mg	Brolucizumab 6 mg
Arm/Group Description	Single intravitreal (IVT) injection of brolucizumab ophthalmic solution administered as a 3 mg/50 microliter (μL) dose at Day 0, Week 4, and Week 8, followed by 1 injection every 8 weeks/1 injection every 12 weeks (q8w/q12w) maintenance regimen until study exit	Single IVT injection of brolucizumab ophthalmic solution administered as a 6 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit
Measure Participants	358	360
Number (95% Confidence Interval) [proportion of subjects]	0.4939	0.5563

4. Secondary Outcome

Title	Proportion of Subjects With Positive q12 Treatment Status at Week 48 Within the Subjects With no q8 (Every 8 Weeks) Treatment Need During the First q12 Cycle (Week 16, Week 20)
Description	Positive q12 treatment status was defined as IVT injections per planned dosing regimen (one injection every 12 weeks "q12w", after the initial three loading injections every 4 weeks "q4w"). A DAA was performed at pre-specified visits (Weeks 16, 20, 28, 32, 40, 44) to identify q8w need. The estimate for the proportion of subjects with a positive q12w status at Week 48 were derived from Kaplan-Meier time to event analyses for the event of first q8w need, applying event allocations (in case of lack of efficacy and/or lack of safety=efficacy/safety approach) and censoring as described in the SAP. Censored subjects were considered to be not anymore under risk for a q8 need identification at later visits. Corresponding 95% CIs were derived from the LOGLOG transformation. No hypothesis testing was performed. This outcome measure was pre-specified for the brolucizumab 3 mg and 6 mg arms only.
Time Frame	Weeks 16, 20, 28, 32, 40, 44, 48

Outcome Measure Data

Analysis Population Description

FAS - efficacy/safety approach

Arm/Group Title	Brolucizumab 3 mg	Brolucizumab 6 mg
Arm/Group Description	Single intravitreal (IVT) injection of brolucizumab ophthalmic solution administered as a 3 mg/50 microliter (μL) dose at Day 0, Week 4, and Week 8, followed by 1 injection every 8 weeks/1 injection every 12 weeks (q8w/q12w) maintenance regimen until study exit	Single IVT injection of brolucizumab ophthalmic solution administered as a 6 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit
Measure Participants	208	222
Number (95% Confidence Interval) [proportion of subjects]	0.8085	0.8539

5. Secondary Outcome

Title	Proportion of Subjects With Positive q12 Treatment Status up to Week 96
Description	Positive q12 treatment status was defined as IVT injections per planned dosing regimen (one injection every 12 weeks "q12w", after the initial three loading injections every 4 weeks "q4w"). A DAA was performed at pre-specified visits (Weeks 16, 20, 28, 32, 40, 44, 52, 56, 64, 68, 76, 80, 88, 92) to identify q8w need. The estimate for the proportion of subjects with a positive q12w status at Week 48 were derived from Kaplan-Meier time to event analyses for the event of first q8w need, applying event allocations (in case of lack of efficacy and/or lack of safety=efficacy/safety approach) and censoring as described in the SAP. Censored subjects were considered to be not anymore under risk for a q8 need identification at later visits. Corresponding 95% CIs were derived from the LOGLOG transformation. No hypothesis testing was performed. This outcome measure was pre-specified for the brolucizumab 3 mg and 6 mg arms only.
Time Frame	Weeks 16, 20, 28, 32, 40, 44, 52, 56, 64, 68, 76, 80, 88, 92, 96

Outcome Measure Data

Analysis Population Description

FAS - efficacy/safety approach

Arm/Group Title	Brolucizumab 3 mg	Brolucizumab 6 mg
Arm/Group Description	Single intravitreal (IVT) injection of brolucizumab ophthalmic solution administered as a 3 mg/50 microliter (μL) dose at Day 0, Week 4, and Week 8, followed by 1 injection every 8 weeks/1 injection every 12 weeks (q8w/q12w) maintenance regimen until study exit	Single IVT injection of brolucizumab ophthalmic solution administered as a 6 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit
Measure Participants	358	360
Number (95% Confidence Interval) [proportion of subjects]	0.3973	0.4537

6. Secondary Outcome

Title	Proportion of Subjects With Positive q12 Treatment Status at Week 96 Within the Subjects With no q8 Treatment Need During the Initial q12 Cycle (Week 16, Week 20)
Description	Positive q12 treatment status was defined as IVT injections per planned dosing regimen (one injection every 12 weeks "q12w", after the initial three loading injections every 4 weeks "q4w"). A DAA was performed at pre-specified visits (Weeks 16, 20, 28, 32, 40, 44, 52, 56, 64, 68, 76, 80, 88, 92) to identify q8w need. The estimate for the proportion of subjects with a positive q12w status at Week 48 were derived from Kaplan-Meier time to event analyses for the event of first q8w need, applying event allocations (in case of lack of efficacy and/or lack of safety=efficacy/safety approach) and censoring as described in the SAP. Censored subjects were considered to be not anymore under risk for a q8 need identification at later visits. Corresponding 95% CIs were derived from the LOGLOG transformation. No hypothesis testing was performed. This outcome measure was pre-specified for the brolucizumab 3 mg and 6 mg arms only.
Time Frame	Weeks 16, 20, 28, 32, 40, 44, 52, 56, 64, 68, 76, 80, 88, 92, 96

Outcome Measure Data

Analysis Population Description

FAS - efficacy/safety approach

Arm/Group Title	Brolucizumab 3 mg	Brolucizumab 6 mg
Arm/Group Description	Single intravitreal (IVT) injection of brolucizumab ophthalmic solution administered as a 3 mg/50 microliter (μL) dose at Day 0, Week 4, and Week 8, followed by 1 injection every 8 weeks/1 injection every 12 weeks (q8w/q12w) maintenance regimen until study exit	Single IVT injection of brolucizumab ophthalmic solution administered as a 6 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit
Measure Participants	208	222
Number (95% Confidence Interval) [proportion of subjects]	0.6504	0.6963

7. Secondary Outcome

Title	Change From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye
Description	BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. One eye (study eye) contributed to the analysis.
Time Frame	Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96

Outcome Measure Data

Analysis Population Description

FAS - LOCF

Arm/Group Title	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Arm/Group Description	Single intravitreal (IVT) injection of brolucizumab ophthalmic solution administered as a 3 mg/50 microliter (μL) dose at Day 0, Week 4, and Week 8, followed by 1 injection every 8 weeks/1 injection every 12 weeks (q8w/q12w) maintenance regimen until study exit	Single IVT injection of brolucizumab ophthalmic solution administered as a 6 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Single IVT injection of aflibercept ophthalmic solution administered as a 2 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Measure Participants	358	360	360
Change from baseline at Week 4	3.7 (8.36)	3.8 (9.77)	4.2 (7.93)
Change from baseline at Week 8	5.7 (8.83)	5.5 (10.71)	6.1 (9.48)
Change from baseline at Week 12	5.7 (10.19)	6.0 (11.71)	6.3 (10.41)
Change from baseline at Week 16	5.7 (11.44)	6.3 (11.65)	6.1 (10.89)
Change from baseline at Week 20	6.2 (11.40)	6.2 (12.30)	7.1 (11.25)
Change from baseline at Week 24	6.1 (11.95)	6.4 (12.50)	6.8 (11.72)
Change from baseline at Week 28	6.2 (12.67)	6.7 (13.23)	6.7 (12.30)
Change from baseline at Week 32	5.6 (13.42)	6.8 (13.41)	6.6 (12.43)
Change from baseline at Week 36	5.6 (13.45)	6.5 (13.74)	7.1 (12.46)
Change from baseline at Week 40	6.2 (13.96)	6.6 (14.55)	6.9 (12.96)
Change from baseline at Week 44	6.2 (14.05)	6.6 (14.01)	6.7 (13.37)
Change from baseline at Week 48	5.9 (13.49)	6.4 (14.40)	7.0 (13.16)
Change from baseline at Week 52	6.2 (14.00)	6.2 (14.58)	6.8 (14.10)
Change from baseline at Week 56	6.2 (14.08)	6.1 (14.88)	7.1 (13.31)
Change from baseline at Week 60	6.2 (14.26)	6.2 (14.72)	6.7 (13.96)
Change from baseline at Week 64	5.9 (14.67)	6.0 (15.16)	6.6 (13.75)
Change from baseline at Week 68	6.0 (14.60)	5.9 (15.10)	6.5 (13.95)
Change from baseline at Week 72	6.0 (14.95)	5.6 (14.80)	6.2 (14.50)
Change from baseline at Week 76	6.2 (14.91)	5.9 (15.09)	6.3 (14.21)
Change from baseline at Week 80	6.1 (14.83)	6.1 (15.33)	5.8 (14.42)
Change from baseline at Week 84	5.8 (15.01)	5.5 (14.94)	5.6 (14.36)
Change from baseline at Week 88	5.8 (15.43)	5.7 (15.45)	5.8 (14.67)
Change from baseline at Week 92	5.8 (15.48)	5.8 (15.21)	5.9 (14.64)
Change from baseline at Week 96	5.4 (15.86)	5.6 (15.62)	5.6 (14.78)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 4
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-0.2
	Confidence Interval	(2-Sided) 95%; -1.4 to 0.9
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 0.59
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-0.1
	Confidence Interval	(2-Sided) 95%; -1.4 to 1.1
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 0.64
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 8
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-0.1
	Confidence Interval	(2-Sided) 95%; -1.4 to 1.2
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 0.67
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 8
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-0.3
	Confidence Interval	(2-Sided) 95%; -1.7 to 1.2
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 0.73
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 5

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 12
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-0.3
	Confidence Interval	(2-Sided) 95%; -1.8 to 1.2
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 0.76
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 6

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 12
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	0.0
	Confidence Interval	(2-Sided) 95%; -1.5 to 1.6
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 0.80
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 7

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 16
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-0.1
	Confidence Interval	(2-Sided) 95%; -1.8 to 1.5
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 0.82
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 8

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 16
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	0.5
	Confidence Interval	(2-Sided) 95%; -1.1 to 2.1
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 0.82
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 9

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 20
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-0.6
	Confidence Interval	(2-Sided) 95%; -2.2 to 1.0
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 0.83
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 10

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 20
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-0.5
	Confidence Interval	(2-Sided) 95%; -2.2 to 1.2
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 0.86
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 11

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 24
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-0.4
	Confidence Interval	(2-Sided) 95%; -2.1 to 1.3
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 0.87
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 12

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 24
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-0.1
	Confidence Interval	(2-Sided) 95%; -1.9 to 1.6
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 0.88
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 13

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 28
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-0.1
	Confidence Interval	(2-Sided) 95%; -1.9 to 1.7
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 0.92
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 14

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 28
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	0.4
	Confidence Interval	(2-Sided) 95%; -1.4 to 2.2
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 0.92
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 15

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 32
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-0.5
	Confidence Interval	(2-Sided) 95%; -2.4 to 1.3
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 0.94
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 16

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 32
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	0.6
	Confidence Interval	(2-Sided) 95%; -1.2 to 2.5
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 0.94
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 17

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 36
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-1.0
	Confidence Interval	(2-Sided) 95%; -2.9 to 0.8
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 0.94
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 18

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 36
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-0.2
	Confidence Interval	(2-Sided) 95%; -2.1 to 1.6
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 0.95
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 19

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 40
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-0.3
	Confidence Interval	(2-Sided) 95%; -2.2 to 1.6
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 0.98
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 20

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 40
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	0.1
	Confidence Interval	(2-Sided) 95%; -1.9 to 2.1
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 1.00
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 21

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 44
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-0.1
	Confidence Interval	(2-Sided) 95%; -2.1 to 1.9
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 1.00
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 22

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 44
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	0.2
	Confidence Interval	(2-Sided) 95%; -1.8 to 2.2
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 1.00
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 23

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 48
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-0.6
	Confidence Interval	(2-Sided) 95%; -2.5 to 1.3
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 0.98
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 24

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 48
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-0.2
	Confidence Interval	(2-Sided) 95%; -2.1 to 1.8
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 1.00
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 25

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 52
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-0.2
	Confidence Interval	(2-Sided) 95%; -2.2 to 1.8
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 1.03
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 26

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 52
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-0.2
	Confidence Interval	(2-Sided) 95%; -2.2 to 1.9
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 1.04
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 27

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 56
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-0.5
	Confidence Interval	(2-Sided) 95%; -2.5 to 1.5
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 1.00
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 28

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 56
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-0.6
	Confidence Interval	(2-Sided) 95%; -2.7 to 1.4
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 1.03
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 29

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 60
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-0.1
	Confidence Interval	(2-Sided) 95%; -2.1 to 1.9
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 1.03
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 30

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 60
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-0.1
	Confidence Interval	(2-Sided) 95%; -2.2 to 1.9
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 1.04
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 31

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 64
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-0.3
	Confidence Interval	(2-Sided) 95%; -2.3 to 1.7
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 1.04
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 32

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 64
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-0.2
	Confidence Interval	(2-Sided) 95%; -2.2 to 1.9
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 1.05
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 33

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 68
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-0.1
	Confidence Interval	(2-Sided) 95%; -2.1 to 2.0
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 1.04
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 34

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 68
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-0.1
	Confidence Interval	(2-Sided) 95%; -2.2 to 1.9
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 1.05
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 35

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 72
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	0.2
	Confidence Interval	(2-Sided) 95%; -2.0 to 2.3
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 1.08
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 36

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 72
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-0.3
	Confidence Interval	(2-Sided) 95%; -2.4 to 1.8
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 1.07
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 37

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 76
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	0.3
	Confidence Interval	(2-Sided) 95%; -1.8 to 2.4
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 1.07
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 38

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 76
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	0.0
	Confidence Interval	(2-Sided) 95%; -2.1 to 2.1
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 1.06
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 39

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 80
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	0.6
	Confidence Interval	(2-Sided) 95%; -1.5 to 2.7
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 1.07
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 40

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 80
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	0.7
	Confidence Interval	(2-Sided) 95%; -1.4 to 2.8
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 1.08
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 41

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 84
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	0.6
	Confidence Interval	(2-Sided) 95%; -1.5 to 2.7
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 1.08
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 42

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 84
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	0.3
	Confidence Interval	(2-Sided) 95%; -1.8 to 2.4
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 1.06
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 43

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 88
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	0.4
	Confidence Interval	(2-Sided) 95%; -1.8 to 2.5
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 1.10
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 44

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 88
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	0.3
	Confidence Interval	(2-Sided) 95%; -1.9 to 2.4
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 1.10
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 45

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 92
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	0.3
	Confidence Interval	(2-Sided) 95%; -1.9 to 2.5
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 1.10
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 46

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 92
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	0.4
	Confidence Interval	(2-Sided) 95%; -1.8 to 2.5
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 1.09
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 47

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 96
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	0.3
	Confidence Interval	(2-Sided) 95%; -1.9 to 2.5
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 1.12
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 48

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 96
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	0.5
	Confidence Interval	(2-Sided) 95%; -1.6 to 2.7
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 1.10
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

8. Secondary Outcome

Title	Average Change From Baseline in BCVA (Letters Read) Over the Period Week 4 to Week 48/96 - Study Eye
Description	BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. One eye (study eye) contributed to the analysis.
Time Frame	Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96

Outcome Measure Data

Analysis Population Description

FAS - LOCF

Arm/Group Title	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Arm/Group Description	Single intravitreal (IVT) injection of brolucizumab ophthalmic solution administered as a 3 mg/50 microliter (μL) dose at Day 0, Week 4, and Week 8, followed by 1 injection every 8 weeks/1 injection every 12 weeks (q8w/q12w) maintenance regimen until study exit	Single IVT injection of brolucizumab ophthalmic solution administered as a 6 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Single IVT injection of aflibercept ophthalmic solution administered as a 2 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Measure Participants	358	360	360
Change from baseline over the period Week 4 to 48	5.7 (10.43)	6.2 (11.62)	6.5 (10.49)
Change from baseline over the period Week 4 to 96	5.8 (12.06)	6.0 (12.73)	6.4 (11.76)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 4 to Week 48
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-0.4
	Confidence Interval	(2-Sided) 95%; -1.9 to 1.1
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 0.76
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 4 to Week 48
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	0.0
	Confidence Interval	(2-Sided) 95%; -1.5 to 1.6
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 0.80
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 4 to Week 96
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-0.1
	Confidence Interval	(2-Sided) 95%; -1.8 to 1.6
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 0.87
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 4 to Week 96
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	0.0
	Confidence Interval	(2-Sided) 95%; -1.7 to 1.8
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 0.88
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

9. Secondary Outcome

Title	Average Change From Baseline in BCVA (Letters Read) Over the Period Week 12 to Week 48/96 - Study Eye
Description	BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. One eye (study eye) contributed to the analysis.
Time Frame	Baseline, Weeks 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96

Outcome Measure Data

Analysis Population Description

FAS - LOCF

Arm/Group Title	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Arm/Group Description	Single intravitreal (IVT) injection of brolucizumab ophthalmic solution administered as a 3 mg/50 microliter (μL) dose at Day 0, Week 4, and Week 8, followed by 1 injection every 8 weeks/1 injection every 12 weeks (q8w/q12w) maintenance regimen until study exit	Single IVT injection of brolucizumab ophthalmic solution administered as a 6 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Single IVT injection of aflibercept ophthalmic solution administered as a 2 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Measure Participants	358	360	360
Change from baseline over the period Week 12 to 48	5.9 (11.45)	6.5 (12.28)	6.7 (11.27)
Change from baseline over the period Week 12 to 96	5.9 (12.76)	6.1 (13.21)	6.5 (12.28)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 12 to Week 48
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-0.4
	Confidence Interval	(2-Sided) 95%; -2.0 to 1.2
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 0.83
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 12 to Week 48
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	0.1
	Confidence Interval	(2-Sided) 95%; -1.6 to 1.8
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 0.85
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 12 to Week 96
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-0.1
	Confidence Interval	(2-Sided) 95%; -1.9 to 1.7
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 0.91
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 12 to Week 96
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	0.1
	Confidence Interval	(2-Sided) 95%; -1.7 to 1.9
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 0.92
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

10. Secondary Outcome

Title	Average Change From Baseline in BCVA (Letters Read) Over the Period Week 84 to Week 96 - Study Eye
Description	BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. One eye (study eye) contributed to the analysis.
Time Frame	Baseline, Weeks 84, 88, 92, 96

Outcome Measure Data

Analysis Population Description

FAS - LOCF

Arm/Group Title	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Arm/Group Description	Single intravitreal (IVT) injection of brolucizumab ophthalmic solution administered as a 3 mg/50 microliter (μL) dose at Day 0, Week 4, and Week 8, followed by 1 injection every 8 weeks/1 injection every 12 weeks (q8w/q12w) maintenance regimen until study exit	Single IVT injection of brolucizumab ophthalmic solution administered as a 6 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Single IVT injection of aflibercept ophthalmic solution administered as a 2 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Measure Participants	358	360	360
Mean (Standard Deviation) [letters]	5.7 (15.15)	5.7 (15.05)	5.7 (14.29)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	0.4
	Confidence Interval	(2-Sided) 95%; -1.7 to 2.5
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 1.08
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	0.4
	Confidence Interval	(2-Sided) 95%; -1.7 to 2.5
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 1.06
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

11. Secondary Outcome

Title	Percentage of Subjects With >=15 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye
Description	BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. 95% CI for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.
Time Frame	Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96

Outcome Measure Data

Analysis Population Description

FAS - LOCF

Arm/Group Title	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Arm/Group Description	Single intravitreal (IVT) injection of brolucizumab ophthalmic solution administered as a 3 mg/50 microliter (μL) dose at Day 0, Week 4, and Week 8, followed by 1 injection every 8 weeks/1 injection every 12 weeks (q8w/q12w) maintenance regimen until study exit	Single IVT injection of brolucizumab ophthalmic solution administered as a 6 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Single IVT injection of aflibercept ophthalmic solution administered as a 2 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Measure Participants	358	360	360
Change from baseline at Week 4	9.2	10.8	9.7
Change from baseline at Week 8	15.9	19.2	15.6
Change from baseline at Week 12	20.1	24.4	20.3
Change from baseline at Week 16	22.6	22.5	20.8
Change from baseline at Week 20	22.6	25.8	22.8
Change from baseline at Week 24	23.2	28.3	21.9
Change from baseline at Week 28	27.4	28.1	25.8
Change from baseline at Week 32	25.4	31.9	25.0
Change from baseline at Week 36	24.9	31.7	24.7
Change from baseline at Week 40	27.1	33.6	26.4
Change from baseline at Week 44	27.7	34.2	27.5
Change from baseline at Week 48	24.9	33.1	25.8
Change from baseline at Week 52	29.9	31.7	28.1
Change from baseline at Week 56	29.9	31.7	29.7
Change from baseline at Week 60	27.7	32.5	28.6
Change from baseline at Week 64	30.7	32.5	27.8
Change from baseline at Week 68	29.9	32.5	28.1
Change from baseline at Week 72	30.4	31.4	27.5
Change from baseline at Week 76	33.8	32.5	28.6
Change from baseline at Week 80	28.5	35.6	27.8
Change from baseline at Week 84	29.3	30.0	26.7
Change from baseline at Week 88	31.0	34.7	27.8
Change from baseline at Week 92	28.8	32.8	28.1
Change from baseline at Week 96	32.1	33.6	27.5

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 4
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.2
	Confidence Interval	(2-Sided) 95%; -4.2 to 4.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 4
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.6
	Confidence Interval	(2-Sided) 95%; -2.8 to 5.8
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 8
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.8
	Confidence Interval	(2-Sided) 95%; -4.4 to 5.9
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 8
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	4.2
	Confidence Interval	(2-Sided) 95%; -1.2 to 10.0
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 5

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 12
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.2
	Confidence Interval	(2-Sided) 95%; -5.9 to 5.9
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 6

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 12
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	4.9
	Confidence Interval	(2-Sided) 95%; -0.5 to 11.0
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 7

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 16
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	2.3
	Confidence Interval	(2-Sided) 95%; -3.7 to 8.0
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 8

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 16
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	2.3
	Confidence Interval	(2-Sided) 95%; -3.8 to 8.3
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 9

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 20
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.3
	Confidence Interval	(2-Sided) 95%; -5.9 to 6.1
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 10

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 20
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	3.8
	Confidence Interval	(2-Sided) 95%; -2.4 to 9.9
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 11

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 24
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.9
	Confidence Interval	(2-Sided) 95%; -4.2 to 7.3
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 12

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 24
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	7.2
	Confidence Interval	(2-Sided) 95%; 0.8 to 13.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 13

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 28
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	2.3
	Confidence Interval	(2-Sided) 95%; -4.3 to 8.5
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 14

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 28
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	3.2
	Confidence Interval	(2-Sided) 95%; -3.4 to 9.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 15

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 32
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.2
	Confidence Interval	(2-Sided) 95%; -5.0 to 7.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 16

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 32
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	7.9
	Confidence Interval	(2-Sided) 95%; 1.5 to 14.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 17

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 36
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.0
	Confidence Interval	(2-Sided) 95%; -5.4 to 7.0
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 18

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 36
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	8.1
	Confidence Interval	(2-Sided) 95%; 2.1 to 14.5
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 19

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 40
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.5
	Confidence Interval	(2-Sided) 95%; -4.4 to 8.1
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 20

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 40
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	8.3
	Confidence Interval	(2-Sided) 95%; 2.0 to 15.1
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 21

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 44
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.0
	Confidence Interval	(2-Sided) 95%; -5.2 to 7.1
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 22

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 44
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	7.6
	Confidence Interval	(2-Sided) 95%; 0.7 to 13.8
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 23

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 48
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.2
	Confidence Interval	(2-Sided) 95%; -6.8 to 6.1
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 24

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 48
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	8.2
	Confidence Interval	(2-Sided) 95%; 2.2 to 15.0
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 25

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 52
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	2.8
	Confidence Interval	(2-Sided) 95%; -3.9 to 9.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 26

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 52
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	4.8
	Confidence Interval	(2-Sided) 95%; -1.5 to 11.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 27

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 56
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.8
	Confidence Interval	(2-Sided) 95%; -5.9 to 7.1
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 28

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 56
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	3.0
	Confidence Interval	(2-Sided) 95%; -3.1 to 9.7
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 29

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 60
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.3
	Confidence Interval	(2-Sided) 95%; -6.5 to 6.5
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 30

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 60
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	4.9
	Confidence Interval	(2-Sided) 95%; -1.3 to 11.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 31

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 64
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	3.7
	Confidence Interval	(2-Sided) 95%; -2.9 to 10.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 32

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 64
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	5.8
	Confidence Interval	(2-Sided) 95%; -0.4 to 12.3
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 33

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 68
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	2.4
	Confidence Interval	(2-Sided) 95%; -4.2 to 9.0
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 34

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 68
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	5.6
	Confidence Interval	(2-Sided) 95%; -0.2 to 11.9
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 35

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 72
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	3.8
	Confidence Interval	(2-Sided) 95%; -3.0 to 9.9
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 36

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 72
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	5.1
	Confidence Interval	(2-Sided) 95%; -1.1 to 11.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 37

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 76
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	6.0
	Confidence Interval	(2-Sided) 95%; -1.5 to 12.8
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 38

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 76
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	5.0
	Confidence Interval	(2-Sided) 95%; -1.0 to 11.6
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 39

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 80
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.7
	Confidence Interval	(2-Sided) 95%; -5.1 to 8.6
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 40

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 80
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	8.8
	Confidence Interval	(2-Sided) 95%; 2.7 to 15.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 41

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 84
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	3.3
	Confidence Interval	(2-Sided) 95%; -3.7 to 9.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 42

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 84
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	4.2
	Confidence Interval	(2-Sided) 95%; -2.2 to 10.3
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 43

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 88
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	4.1
	Confidence Interval	(2-Sided) 95%; -3.0 to 10.9
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 44

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 88
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	8.0
	Confidence Interval	(2-Sided) 95%; 1.9 to 14.6
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 45

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 92
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.6
	Confidence Interval	(2-Sided) 95%; -5.1 to 8.3
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 46

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 92
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	5.9
	Confidence Interval	(2-Sided) 95%; -0.0 to 12.5
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 47

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 96
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	5.5
	Confidence Interval	(2-Sided) 95%; -1.2 to 12.3
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 48

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 96
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	7.2
	Confidence Interval	(2-Sided) 95%; 1.4 to 13.8
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

12. Secondary Outcome

Title	Percentage of Subjects With >=10 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye
Description	BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. 95% CI for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.
Time Frame	Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96

Outcome Measure Data

Analysis Population Description

FAS - LOCF

Arm/Group Title	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Arm/Group Description	Single intravitreal (IVT) injection of brolucizumab ophthalmic solution administered as a 3 mg/50 microliter (μL) dose at Day 0, Week 4, and Week 8, followed by 1 injection every 8 weeks/1 injection every 12 weeks (q8w/q12w) maintenance regimen until study exit	Single IVT injection of brolucizumab ophthalmic solution administered as a 6 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Single IVT injection of aflibercept ophthalmic solution administered as a 2 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Measure Participants	358	360	360
Change from baseline at Week 4	19.3	24.4	19.2
Change from baseline at Week 8	30.7	32.5	32.2
Change from baseline at Week 12	33.2	38.6	33.9
Change from baseline at Week 16	35.2	39.7	35.6
Change from baseline at Week 20	37.2	42.2	38.3
Change from baseline at Week 24	40.2	41.9	39.4
Change from baseline at Week 28	41.1	43.9	41.4
Change from baseline at Week 32	38.3	43.9	41.7
Change from baseline at Week 36	41.1	43.3	43.1
Change from baseline at Week 40	41.3	45.3	44.2
Change from baseline at Week 44	44.4	43.1	44.2
Change from baseline at Week 48	41.3	45.3	44.2
Change from baseline at Week 52	43.0	43.9	44.2
Change from baseline at Week 56	44.4	42.5	45.3
Change from baseline at Week 60	41.6	45.6	43.6
Change from baseline at Week 64	43.0	44.7	40.6
Change from baseline at Week 68	44.7	44.2	43.6
Change from baseline at Week 72	45.3	41.9	41.9
Change from baseline at Week 76	45.0	44.4	44.4
Change from baseline at Week 80	41.3	43.6	43.3
Change from baseline at Week 84	43.3	42.8	42.2
Change from baseline at Week 88	44.4	43.6	41.7
Change from baseline at Week 92	44.1	43.3	40.8
Change from baseline at Week 96	43.6	43.9	39.7

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 4
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.3
	Confidence Interval	(2-Sided) 95%; -4.3 to 6.9
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 4
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	6.3
	Confidence Interval	(2-Sided) 95%; 0.6 to 12.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 8
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.3
	Confidence Interval	(2-Sided) 95%; -6.6 to 6.7
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 8
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.7
	Confidence Interval	(2-Sided) 95%; -4.7 to 8.0
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 5

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 12
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.5
	Confidence Interval	(2-Sided) 95%; -6.2 to 7.1
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 6

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 12
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	6.0
	Confidence Interval	(2-Sided) 95%; -0.8 to 12.7
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 7

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 16
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.0
	Confidence Interval	(2-Sided) 95%; -6.0 to 7.7
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 8

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 16
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	5.6
	Confidence Interval	(2-Sided) 95%; -1.5 to 12.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 9

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 20
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.3
	Confidence Interval	(2-Sided) 95%; -6.5 to 7.0
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 10

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 20
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	5.2
	Confidence Interval	(2-Sided) 95%; -1.8 to 12.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 11

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 24
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	2.5
	Confidence Interval	(2-Sided) 95%; -4.0 to 9.5
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 12

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 24
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	3.8
	Confidence Interval	(2-Sided) 95%; -3.5 to 11.3
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 13

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 28
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.2
	Confidence Interval	(2-Sided) 95%; -5.9 to 8.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 14

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 28
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	3.9
	Confidence Interval	(2-Sided) 95%; -3.4 to 11.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 15

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 32
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-1.6
	Confidence Interval	(2-Sided) 95%; -8.2 to 5.9
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 16

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 32
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	3.6
	Confidence Interval	(2-Sided) 95%; -3.2 to 10.5
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 17

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 36
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.1
	Confidence Interval	(2-Sided) 95%; -7.3 to 6.8
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 18

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 36
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.9
	Confidence Interval	(2-Sided) 95%; -5.2 to 8.6
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 19

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 40
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.9
	Confidence Interval	(2-Sided) 95%; -7.8 to 6.6
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 20

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 40
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	2.3
	Confidence Interval	(2-Sided) 95%; -4.8 to 10.0
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 21

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 44
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	2.2
	Confidence Interval	(2-Sided) 95%; -4.4 to 9.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 22

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 44
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.2
	Confidence Interval	(2-Sided) 95%; -7.1 to 7.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 23

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 48
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-1.0
	Confidence Interval	(2-Sided) 95%; -7.9 to 6.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 24

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 48
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	2.4
	Confidence Interval	(2-Sided) 95%; -4.5 to 9.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 25

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 52
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.5
	Confidence Interval	(2-Sided) 95%; -6.8 to 8.1
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 26

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 52
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.2
	Confidence Interval	(2-Sided) 95%; -5.8 to 8.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 27

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 56
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.0
	Confidence Interval	(2-Sided) 95%; -6.1 to 8.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 28

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 56
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-1.3
	Confidence Interval	(2-Sided) 95%; -8.6 to 5.6
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 29

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 60
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.3
	Confidence Interval	(2-Sided) 95%; -7.0 to 7.1
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 30

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 60
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	3.4
	Confidence Interval	(2-Sided) 95%; -3.5 to 11.0
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 31

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 64
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	4.0
	Confidence Interval	(2-Sided) 95%; -3.0 to 10.8
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 32

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 64
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	5.5
	Confidence Interval	(2-Sided) 95%; -1.4 to 13.0
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 33

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 68
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	2.7
	Confidence Interval	(2-Sided) 95%; -4.1 to 9.5
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 34

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 68
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	2.1
	Confidence Interval	(2-Sided) 95%; -4.8 to 9.7
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 35

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 72
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	5.2
	Confidence Interval	(2-Sided) 95%; -1.6 to 12.3
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 36

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 72
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.6
	Confidence Interval	(2-Sided) 95%; -5.4 to 8.6
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 37

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 76
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	2.5
	Confidence Interval	(2-Sided) 95%; -4.8 to 9.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 38

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 76
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.5
	Confidence Interval	(2-Sided) 95%; -5.0 to 8.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 39

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 80
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.1
	Confidence Interval	(2-Sided) 95%; -6.9 to 7.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 40

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 80
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.7
	Confidence Interval	(2-Sided) 95%; -5.1 to 8.5
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 41

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 84
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	3.0
	Confidence Interval	(2-Sided) 95%; -3.9 to 10.1
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 42

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 84
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	2.1
	Confidence Interval	(2-Sided) 95%; -5.0 to 9.1
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 43

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 88
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	4.6
	Confidence Interval	(2-Sided) 95%; -2.5 to 11.8
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 44

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 88
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	3.3
	Confidence Interval	(2-Sided) 95%; -3.4 to 10.6
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 45

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 92
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	5.1
	Confidence Interval	(2-Sided) 95%; -1.6 to 12.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 46

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 92
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	3.9
	Confidence Interval	(2-Sided) 95%; -3.0 to 11.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 47

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 96
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	5.6
	Confidence Interval	(2-Sided) 95%; -1.9 to 12.7
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 48

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 96
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	5.7
	Confidence Interval	(2-Sided) 95%; -1.0 to 12.6
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

13. Secondary Outcome

Title	Percentage of Subjects With >=5 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye
Description	BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. 95% CI for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.
Time Frame	Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96

Outcome Measure Data

Analysis Population Description

FAS - LOCF

Arm/Group Title	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Arm/Group Description	Single intravitreal (IVT) injection of brolucizumab ophthalmic solution administered as a 3 mg/50 microliter (μL) dose at Day 0, Week 4, and Week 8, followed by 1 injection every 8 weeks/1 injection every 12 weeks (q8w/q12w) maintenance regimen until study exit	Single IVT injection of brolucizumab ophthalmic solution administered as a 6 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Single IVT injection of aflibercept ophthalmic solution administered as a 2 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Measure Participants	358	360	360
Change from baseline at Week 4	40.2	43.3	43.1
Change from baseline at Week 8	54.2	53.1	56.1
Change from baseline at Week 12	54.7	58.6	57.8
Change from baseline at Week 16	54.7	59.2	58.6
Change from baseline at Week 20	57.5	56.9	62.2
Change from baseline at Week 24	59.2	63.1	61.7
Change from baseline at Week 28	60.1	61.7	61.7
Change from baseline at Week 32	60.1	61.7	59.7
Change from baseline at Week 36	58.1	59.2	65.8
Change from baseline at Week 40	60.1	63.1	63.1
Change from baseline at Week 44	60.9	62.5	65.6
Change from baseline at Week 48	59.2	61.1	65.6
Change from baseline at Week 52	61.5	60.6	64.2
Change from baseline at Week 56	62.3	60.8	62.2
Change from baseline at Week 60	61.7	60.6	61.9
Change from baseline at Week 64	59.5	61.4	61.9
Change from baseline at Week 68	61.2	60.3	64.7
Change from baseline at Week 72	59.8	60.6	60.0
Change from baseline at Week 76	60.3	60.3	59.7
Change from baseline at Week 80	60.1	58.1	58.3
Change from baseline at Week 84	58.9	58.6	58.6
Change from baseline at Week 88	58.9	57.8	61.7
Change from baseline at Week 92	59.2	58.3	61.4
Change from baseline at Week 96	61.7	58.1	58.6

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 4
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.8
	Confidence Interval	(2-Sided) 95%; -7.7 to 6.0
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 4
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.4
	Confidence Interval	(2-Sided) 95%; -5.3 to 8.7
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 8
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.3
	Confidence Interval	(2-Sided) 95%; -7.4 to 6.8
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 8
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-1.8
	Confidence Interval	(2-Sided) 95%; -8.9 to 5.3
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 5

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 12
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-1.4
	Confidence Interval	(2-Sided) 95%; -8.1 to 5.9
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 6

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 12
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	2.1
	Confidence Interval	(2-Sided) 95%; -4.8 to 8.8
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 7

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 16
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-2.4
	Confidence Interval	(2-Sided) 95%; -9.8 to 4.7
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 8

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 16
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.5
	Confidence Interval	(2-Sided) 95%; -5.3 to 8.6
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 9

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 20
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-3.1
	Confidence Interval	(2-Sided) 95%; -9.7 to 3.6
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 10

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 20
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-4.1
	Confidence Interval	(2-Sided) 95%; -11.4 to 3.3
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 11

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 24
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.9
	Confidence Interval	(2-Sided) 95%; -7.6 to 6.1
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 12

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 24
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	2.5
	Confidence Interval	(2-Sided) 95%; -4.4 to 10.0
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 13

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 28
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.2
	Confidence Interval	(2-Sided) 95%; -7.2 to 6.9
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 14

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 28
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.1
	Confidence Interval	(2-Sided) 95%; -6.3 to 7.8
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 15

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 32
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	2.0
	Confidence Interval	(2-Sided) 95%; -4.7 to 9.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 16

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 32
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	3.1
	Confidence Interval	(2-Sided) 95%; -3.9 to 10.3
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 17

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 36
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-6.0
	Confidence Interval	(2-Sided) 95%; -12.6 to 1.3
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 18

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 36
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-5.4
	Confidence Interval	(2-Sided) 95%; -12.7 to 1.9
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 19

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 40
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-1.6
	Confidence Interval	(2-Sided) 95%; -8.1 to 5.6
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 20

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 40
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.9
	Confidence Interval	(2-Sided) 95%; -6.2 to 7.9
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 21

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 44
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-3.0
	Confidence Interval	(2-Sided) 95%; -9.6 to 3.9
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 22

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 44
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-2.0
	Confidence Interval	(2-Sided) 95%; -9.1 to 5.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 23

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 48
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-4.6
	Confidence Interval	(2-Sided) 95%; -11.1 to 2.1
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 24

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 48
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-3.5
	Confidence Interval	(2-Sided) 95%; -10.4 to 3.5
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 25

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 52
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-1.0
	Confidence Interval	(2-Sided) 95%; -8.0 to 5.7
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 26

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 52
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-2.7
	Confidence Interval	(2-Sided) 95%; -9.7 to 4.8
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 27

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 56
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.4
	Confidence Interval	(2-Sided) 95%; -5.5 to 7.9
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 28

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 56
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.6
	Confidence Interval	(2-Sided) 95%; -7.2 to 6.5
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 29

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 60
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.0
	Confidence Interval	(2-Sided) 95%; -5.8 to 8.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 30

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 60
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.3
	Confidence Interval	(2-Sided) 95%; -7.2 to 6.9
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 31

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 64
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-1.0
	Confidence Interval	(2-Sided) 95%; -7.9 to 5.5
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 32

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 64
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.5
	Confidence Interval	(2-Sided) 95%; -6.6 to 7.9
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 33

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 68
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-2.1
	Confidence Interval	(2-Sided) 95%; -9.4 to 5.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 34

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 68
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-3.1
	Confidence Interval	(2-Sided) 95%; -10.0 to 4.0
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 35

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 72
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.4
	Confidence Interval	(2-Sided) 95%; -6.2 to 8.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 36

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 72
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.7
	Confidence Interval	(2-Sided) 95%; -5.5 to 9.3
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 37

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 76
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	2.4
	Confidence Interval	(2-Sided) 95%; -5.1 to 9.6
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 38

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 76
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.9
	Confidence Interval	(2-Sided) 95%; -5.0 to 8.9
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 39

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 80
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	3.2
	Confidence Interval	(2-Sided) 95%; -3.9 to 10.3
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 40

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 80
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.8
	Confidence Interval	(2-Sided) 95%; -6.1 to 8.1
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 41

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 84
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.9
	Confidence Interval	(2-Sided) 95%; -5.1 to 8.9
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 42

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 84
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.3
	Confidence Interval	(2-Sided) 95%; -5.9 to 8.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 43

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 88
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-1.2
	Confidence Interval	(2-Sided) 95%; -8.5 to 5.8
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 44

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 88
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-2.5
	Confidence Interval	(2-Sided) 95%; -9.7 to 4.7
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 45

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 92
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.4
	Confidence Interval	(2-Sided) 95%; -7.9 to 6.5
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 46

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 92
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-2.1
	Confidence Interval	(2-Sided) 95%; -9.1 to 5.5
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 47

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 96
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	4.6
	Confidence Interval	(2-Sided) 95%; -2.9 to 11.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 48

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 96
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.6
	Confidence Interval	(2-Sided) 95%; -6.6 to 8.0
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

14. Secondary Outcome

Title	Percentage of Subjects With >=15 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye
Description	BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. 95% CI for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.
Time Frame	Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96

Outcome Measure Data

Analysis Population Description

FAS - LOCF

Arm/Group Title	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Arm/Group Description	Single intravitreal (IVT) injection of brolucizumab ophthalmic solution administered as a 3 mg/50 microliter (μL) dose at Day 0, Week 4, and Week 8, followed by 1 injection every 8 weeks/1 injection every 12 weeks (q8w/q12w) maintenance regimen until study exit	Single IVT injection of brolucizumab ophthalmic solution administered as a 6 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Single IVT injection of aflibercept ophthalmic solution administered as a 2 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Measure Participants	358	360	360
Change from baseline at Week 4	1.7	3.1	1.4
Change from baseline at Week 8	1.7	2.8	2.2
Change from baseline at Week 12	3.4	3.6	3.9
Change from baseline at Week 16	3.1	3.6	3.3
Change from baseline at Week 20	2.5	4.7	2.5
Change from baseline at Week 24	4.2	5.3	3.9
Change from baseline at Week 28	4.7	5.6	4.4
Change from baseline at Week 32	5.3	6.4	4.2
Change from baseline at Week 36	4.7	6.4	3.3
Change from baseline at Week 40	5.0	6.9	4.2
Change from baseline at Week 44	5.6	6.4	4.4
Change from baseline at Week 48	5.9	6.4	5.6
Change from baseline at Week 52	6.1	6.9	5.8
Change from baseline at Week 56	6.4	7.8	5.3
Change from baseline at Week 60	5.9	6.9	5.8
Change from baseline at Week 64	7.3	8.6	5.8
Change from baseline at Week 68	7.3	7.5	6.4
Change from baseline at Week 72	7.3	7.5	6.1
Change from baseline at Week 76	6.7	8.1	6.1
Change from baseline at Week 80	7.3	7.8	8.1
Change from baseline at Week 84	8.7	7.8	7.2
Change from baseline at Week 88	8.7	8.1	8.1
Change from baseline at Week 92	8.7	8.1	6.9
Change from baseline at Week 96	8.7	8.1	7.5

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 4
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.4
	Confidence Interval	(2-Sided) 95%; -1.4 to 2.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 4
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.7
	Confidence Interval	(2-Sided) 95%; -0.5 to 4.0
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 8
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.6
	Confidence Interval	(2-Sided) 95%; -2.6 to 1.5
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 8
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.7
	Confidence Interval	(2-Sided) 95%; -1.7 to 2.9
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 5

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 12
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.6
	Confidence Interval	(2-Sided) 95%; -3.3 to 2.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 6

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 12
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.3
	Confidence Interval	(2-Sided) 95%; -3.2 to 2.7
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 7

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 16
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.3
	Confidence Interval	(2-Sided) 95%; -3.0 to 2.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 8

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 16
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.3
	Confidence Interval	(2-Sided) 95%; -2.4 to 3.1
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 9

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 20
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.0
	Confidence Interval	(2-Sided) 95%; -2.2 to 2.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 10

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 20
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	2.3
	Confidence Interval	(2-Sided) 95%; -0.3 to 5.3
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 11

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 24
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.3
	Confidence Interval	(2-Sided) 95%; -2.6 to 3.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 12

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 24
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.5
	Confidence Interval	(2-Sided) 95%; -1.8 to 4.6
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 13

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 28
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.2
	Confidence Interval	(2-Sided) 95%; -2.9 to 3.3
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 14

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 28
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.1
	Confidence Interval	(2-Sided) 95%; -2.3 to 4.6
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 15

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 32
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.0
	Confidence Interval	(2-Sided) 95%; -2.0 to 4.1
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 16

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 32
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	2.2
	Confidence Interval	(2-Sided) 95%; -1.0 to 5.7
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 17

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 36
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.4
	Confidence Interval	(2-Sided) 95%; -1.5 to 4.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 18

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 36
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	3.1
	Confidence Interval	(2-Sided) 95%; 0.0 to 6.5
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 19

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 40
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.9
	Confidence Interval	(2-Sided) 95%; -2.1 to 3.9
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 20

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 40
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	2.8
	Confidence Interval	(2-Sided) 95%; -0.7 to 6.3
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 21

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 44
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.1
	Confidence Interval	(2-Sided) 95%; -2.2 to 4.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 22

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 44
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	2.0
	Confidence Interval	(2-Sided) 95%; -1.4 to 5.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 23

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 48
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.3
	Confidence Interval	(2-Sided) 95%; -3.2 to 3.9
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 24

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 48
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.9
	Confidence Interval	(2-Sided) 95%; -2.7 to 4.3
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 25

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 52
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.3
	Confidence Interval	(2-Sided) 95%; -3.3 to 4.0
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 26

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 52
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.3
	Confidence Interval	(2-Sided) 95%; -2.5 to 4.8
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 27

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 56
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.1
	Confidence Interval	(2-Sided) 95%; -2.4 to 4.6
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 28

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 56
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	2.6
	Confidence Interval	(2-Sided) 95%; -1.5 to 6.3
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 29

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 60
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.1
	Confidence Interval	(2-Sided) 95%; -3.5 to 3.6
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 30

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 60
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.2
	Confidence Interval	(2-Sided) 95%; -2.9 to 4.9
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 31

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 64
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.5
	Confidence Interval	(2-Sided) 95%; -2.4 to 5.1
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 32

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 64
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	2.8
	Confidence Interval	(2-Sided) 95%; -1.3 to 6.7
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 33

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 68
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.8
	Confidence Interval	(2-Sided) 95%; -3.1 to 4.5
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 34

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 68
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.1
	Confidence Interval	(2-Sided) 95%; -2.9 to 4.9
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 35

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 72
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.2
	Confidence Interval	(2-Sided) 95%; -2.6 to 4.7
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 36

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 72
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.5
	Confidence Interval	(2-Sided) 95%; -2.7 to 5.3
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 37

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 76
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.6
	Confidence Interval	(2-Sided) 95%; -3.1 to 4.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 38

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 76
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	2.0
	Confidence Interval	(2-Sided) 95%; -2.1 to 6.0
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 39

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 80
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.8
	Confidence Interval	(2-Sided) 95%; -4.8 to 3.1
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 40

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 80
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.2
	Confidence Interval	(2-Sided) 95%; -4.6 to 3.9
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 41

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 84
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.4
	Confidence Interval	(2-Sided) 95%; -2.6 to 5.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 42

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 84
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.6
	Confidence Interval	(2-Sided) 95%; -3.7 to 4.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 43

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 88
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.6
	Confidence Interval	(2-Sided) 95%; -3.7 to 4.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 44

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 88
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.1
	Confidence Interval	(2-Sided) 95%; -4.1 to 4.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 45

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 92
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.7
	Confidence Interval	(2-Sided) 95%; -2.2 to 5.5
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 46

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 92
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.2
	Confidence Interval	(2-Sided) 95%; -3.0 to 5.1
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 47

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 96
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.1
	Confidence Interval	(2-Sided) 95%; -2.9 to 4.9
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 48

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 96
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.7
	Confidence Interval	(2-Sided) 95%; -3.6 to 4.6
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

15. Secondary Outcome

Title	Percentage of Subjects With >=10 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye
Description	BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. 95% CI for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.
Time Frame	Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96

Outcome Measure Data

Analysis Population Description

FAS - LOCF

Arm/Group Title	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Arm/Group Description	Single intravitreal (IVT) injection of brolucizumab ophthalmic solution administered as a 3 mg/50 microliter (μL) dose at Day 0, Week 4, and Week 8, followed by 1 injection every 8 weeks/1 injection every 12 weeks (q8w/q12w) maintenance regimen until study exit	Single IVT injection of brolucizumab ophthalmic solution administered as a 6 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Single IVT injection of aflibercept ophthalmic solution administered as a 2 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Measure Participants	358	360	360
Change from baseline at Week 4	3.6	4.4	4.2
Change from baseline at Week 8	3.4	3.9	3.9
Change from baseline at Week 12	4.7	5.8	5.8
Change from baseline at Week 16	5.0	4.2	5.6
Change from baseline at Week 20	4.5	6.4	5.3
Change from baseline at Week 24	5.9	8.6	6.4
Change from baseline at Week 28	7.8	7.8	7.2
Change from baseline at Week 32	7.8	7.8	7.2
Change from baseline at Week 36	8.4	8.9	6.9
Change from baseline at Week 40	8.1	9.2	8.3
Change from baseline at Week 44	8.7	8.6	8.1
Change from baseline at Week 48	9.5	8.9	7.5
Change from baseline at Week 52	8.9	11.1	8.3
Change from baseline at Week 56	9.8	10.3	7.8
Change from baseline at Week 60	8.9	10.6	9.4
Change from baseline at Week 64	10.6	11.1	9.2
Change from baseline at Week 68	10.3	11.4	9.2
Change from baseline at Week 72	10.3	11.1	12.2
Change from baseline at Week 76	8.9	12.2	10.0
Change from baseline at Week 80	9.8	12.5	10.8
Change from baseline at Week 84	11.5	12.8	10.8
Change from baseline at Week 88	11.7	12.2	12.2
Change from baseline at Week 92	11.5	11.7	11.9
Change from baseline at Week 96	12.0	14.7	12.5

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 4
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.7
	Confidence Interval	(2-Sided) 95%; -3.7 to 2.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 4
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.3
	Confidence Interval	(2-Sided) 95%; -2.6 to 3.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 8
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.6
	Confidence Interval	(2-Sided) 95%; -3.3 to 2.3
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 8
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.0
	Confidence Interval	(2-Sided) 95%; -3.0 to 2.9
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 5

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 12
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-1.2
	Confidence Interval	(2-Sided) 95%; -4.6 to 2.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 6

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 12
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.1
	Confidence Interval	(2-Sided) 95%; -3.5 to 3.6
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 7

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 16
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.6
	Confidence Interval	(2-Sided) 95%; -4.2 to 2.9
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 8

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 16
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-1.5
	Confidence Interval	(2-Sided) 95%; -5.0 to 2.0
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 9

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 20
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.9
	Confidence Interval	(2-Sided) 95%; -4.1 to 2.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 10

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 20
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.1
	Confidence Interval	(2-Sided) 95%; -2.3 to 4.7
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 11

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 24
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.5
	Confidence Interval	(2-Sided) 95%; -3.9 to 3.1
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 12

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 24
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	2.3
	Confidence Interval	(2-Sided) 95%; -1.8 to 6.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 13

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 28
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.5
	Confidence Interval	(2-Sided) 95%; -3.5 to 4.7
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 14

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 28
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.6
	Confidence Interval	(2-Sided) 95%; -3.6 to 4.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 15

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 32
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.6
	Confidence Interval	(2-Sided) 95%; -3.2 to 4.6
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 16

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 32
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.6
	Confidence Interval	(2-Sided) 95%; -3.2 to 4.5
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 17

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 36
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.2
	Confidence Interval	(2-Sided) 95%; -2.6 to 5.3
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 18

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 36
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.9
	Confidence Interval	(2-Sided) 95%; -2.1 to 5.9
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 19

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 40
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.2
	Confidence Interval	(2-Sided) 95%; -4.3 to 3.9
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 20

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 40
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.8
	Confidence Interval	(2-Sided) 95%; -3.6 to 4.8
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 21

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 44
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.6
	Confidence Interval	(2-Sided) 95%; -3.7 to 4.8
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 22

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 44
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.7
	Confidence Interval	(2-Sided) 95%; -3.7 to 4.7
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 23

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 48
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.9
	Confidence Interval	(2-Sided) 95%; -2.2 to 6.1
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 24

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 48
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.3
	Confidence Interval	(2-Sided) 95%; -2.9 to 5.3
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 25

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 52
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.6
	Confidence Interval	(2-Sided) 95%; -3.5 to 4.8
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 26

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 52
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	3.0
	Confidence Interval	(2-Sided) 95%; -1.6 to 7.3
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 27

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 56
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	2.0
	Confidence Interval	(2-Sided) 95%; -2.3 to 6.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 28

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 56
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	2.5
	Confidence Interval	(2-Sided) 95%; -2.2 to 6.7
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 29

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 60
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.4
	Confidence Interval	(2-Sided) 95%; -4.8 to 3.8
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 30

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 60
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.2
	Confidence Interval	(2-Sided) 95%; -3.8 to 5.9
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 31

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 64
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.4
	Confidence Interval	(2-Sided) 95%; -3.1 to 5.7
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 32

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 64
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	2.0
	Confidence Interval	(2-Sided) 95%; -2.8 to 6.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 33

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 68
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.1
	Confidence Interval	(2-Sided) 95%; -3.4 to 5.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 34

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 68
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	2.3
	Confidence Interval	(2-Sided) 95%; -2.8 to 6.6
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 35

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 72
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-1.9
	Confidence Interval	(2-Sided) 95%; -6.6 to 2.5
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 36

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 72
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.9
	Confidence Interval	(2-Sided) 95%; -6.1 to 3.8
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 37

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 76
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-1.1
	Confidence Interval	(2-Sided) 95%; -5.6 to 3.1
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 38

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 76
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	2.3
	Confidence Interval	(2-Sided) 95%; -2.9 to 6.9
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 39

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 80
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-1.2
	Confidence Interval	(2-Sided) 95%; -5.8 to 3.1
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 40

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 80
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.7
	Confidence Interval	(2-Sided) 95%; -3.2 to 6.5
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 41

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 84
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.5
	Confidence Interval	(2-Sided) 95%; -4.2 to 5.0
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 42

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 84
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.9
	Confidence Interval	(2-Sided) 95%; -3.2 to 6.7
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 43

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 88
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.5
	Confidence Interval	(2-Sided) 95%; -5.8 to 4.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 44

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 88
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.1
	Confidence Interval	(2-Sided) 95%; -5.2 to 4.6
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 45

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 92
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.6
	Confidence Interval	(2-Sided) 95%; -5.5 to 4.1
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 46

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 92
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.2
	Confidence Interval	(2-Sided) 95%; -5.3 to 4.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 47

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 96
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.8
	Confidence Interval	(2-Sided) 95%; -5.7 to 4.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 48

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 96
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	2.1
	Confidence Interval	(2-Sided) 95%; -3.4 to 7.3
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

16. Secondary Outcome

Title	Percentage of Subjects With >=5 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye
Description	BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. 95% CI for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.
Time Frame	Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96

Outcome Measure Data

Analysis Population Description

FAS - LOCF

Arm/Group Title	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Arm/Group Description	Single intravitreal (IVT) injection of brolucizumab ophthalmic solution administered as a 3 mg/50 microliter (μL) dose at Day 0, Week 4, and Week 8, followed by 1 injection every 8 weeks/1 injection every 12 weeks (q8w/q12w) maintenance regimen until study exit	Single IVT injection of brolucizumab ophthalmic solution administered as a 6 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Single IVT injection of aflibercept ophthalmic solution administered as a 2 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Measure Participants	358	360	360
Change from baseline at Week 4	9.8	10.3	7.8
Change from baseline at Week 8	7.5	10.3	7.5
Change from baseline at Week 12	10.3	11.9	8.3
Change from baseline at Week 16	10.3	9.4	10.8
Change from baseline at Week 20	8.7	11.9	10.0
Change from baseline at Week 24	10.3	15.0	11.1
Change from baseline at Week 28	10.6	13.6	12.8
Change from baseline at Week 32	12.8	12.2	13.3
Change from baseline at Week 36	14.0	13.1	10.8
Change from baseline at Week 40	12.0	13.6	13.1
Change from baseline at Week 44	13.7	12.8	14.4
Change from baseline at Week 48	13.7	12.5	11.7
Change from baseline at Week 52	14.0	15.0	13.6
Change from baseline at Week 56	13.4	13.9	12.5
Change from baseline at Week 60	13.7	15.0	13.3
Change from baseline at Week 64	15.4	16.1	13.3
Change from baseline at Week 68	14.2	15.3	14.7
Change from baseline at Week 72	15.9	15.0	14.7
Change from baseline at Week 76	15.9	16.1	15.0
Change from baseline at Week 80	16.2	16.7	15.6
Change from baseline at Week 84	17.9	19.2	15.8
Change from baseline at Week 88	17.0	17.5	16.1
Change from baseline at Week 92	17.3	17.5	16.1
Change from baseline at Week 96	20.4	18.9	17.2

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 4
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.6
	Confidence Interval	(2-Sided) 95%; -2.4 to 5.5
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 4
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	2.4
	Confidence Interval	(2-Sided) 95%; -1.8 to 6.8
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 8
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.2
	Confidence Interval	(2-Sided) 95%; -4.1 to 3.8
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 8
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	2.7
	Confidence Interval	(2-Sided) 95%; -1.7 to 6.8
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 5

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 12
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.8
	Confidence Interval	(2-Sided) 95%; -2.3 to 6.5
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 6

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 12
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	3.4
	Confidence Interval	(2-Sided) 95%; -0.9 to 7.9
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 7

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 16
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.7
	Confidence Interval	(2-Sided) 95%; -5.4 to 4.0
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 8

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 16
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-1.6
	Confidence Interval	(2-Sided) 95%; -6.2 to 3.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 9

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 20
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-1.3
	Confidence Interval	(2-Sided) 95%; -5.4 to 3.3
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 10

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 20
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	2.0
	Confidence Interval	(2-Sided) 95%; -2.9 to 6.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 11

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 24
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.8
	Confidence Interval	(2-Sided) 95%; -5.2 to 3.9
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 12

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 24
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	3.8
	Confidence Interval	(2-Sided) 95%; -1.4 to 8.8
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 13

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 28
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-2.3
	Confidence Interval	(2-Sided) 95%; -6.8 to 2.3
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 14

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 28
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.8
	Confidence Interval	(2-Sided) 95%; -4.7 to 5.8
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 15

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 32
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.5
	Confidence Interval	(2-Sided) 95%; -5.0 to 4.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 16

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 32
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-1.1
	Confidence Interval	(2-Sided) 95%; -6.1 to 4.0
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 17

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 36
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	2.8
	Confidence Interval	(2-Sided) 95%; -1.8 to 7.7
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 18

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 36
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	2.1
	Confidence Interval	(2-Sided) 95%; -2.7 to 6.8
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 19

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 40
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-1.1
	Confidence Interval	(2-Sided) 95%; -5.9 to 4.0
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 20

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 40
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.4
	Confidence Interval	(2-Sided) 95%; -4.7 to 4.9
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 21

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 44
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.7
	Confidence Interval	(2-Sided) 95%; -5.7 to 4.5
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 22

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 44
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-1.6
	Confidence Interval	(2-Sided) 95%; -6.5 to 3.3
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 23

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 48
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	2.1
	Confidence Interval	(2-Sided) 95%; -2.7 to 6.9
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 24

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 48
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.8
	Confidence Interval	(2-Sided) 95%; -4.3 to 5.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 25

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 52
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.2
	Confidence Interval	(2-Sided) 95%; -4.6 to 5.3
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 26

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 52
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.6
	Confidence Interval	(2-Sided) 95%; -3.9 to 6.6
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 27

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 56
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.9
	Confidence Interval	(2-Sided) 95%; -4.0 to 6.1
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 28

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 56
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.5
	Confidence Interval	(2-Sided) 95%; -3.8 to 6.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 29

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 60
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.4
	Confidence Interval	(2-Sided) 95%; -4.5 to 5.6
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 30

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 60
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.7
	Confidence Interval	(2-Sided) 95%; -3.8 to 6.8
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 31

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 64
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	2.2
	Confidence Interval	(2-Sided) 95%; -2.9 to 7.3
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 32

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 64
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	2.9
	Confidence Interval	(2-Sided) 95%; -2.8 to 7.9
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 33

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 68
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.5
	Confidence Interval	(2-Sided) 95%; -5.5 to 4.5
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 34

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 68
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.5
	Confidence Interval	(2-Sided) 95%; -5.1 to 5.3
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 35

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 72
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.2
	Confidence Interval	(2-Sided) 95%; -4.3 to 6.7
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 36

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 72
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.5
	Confidence Interval	(2-Sided) 95%; -5.2 to 5.6
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 37

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 76
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.9
	Confidence Interval	(2-Sided) 95%; -4.6 to 6.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 38

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 76
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.2
	Confidence Interval	(2-Sided) 95%; -4.7 to 6.3
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 39

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 80
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.7
	Confidence Interval	(2-Sided) 95%; -4.8 to 6.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 40

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 80
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.1
	Confidence Interval	(2-Sided) 95%; -4.8 to 6.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 41

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 84
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	2.2
	Confidence Interval	(2-Sided) 95%; -3.1 to 7.7
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 42

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 84
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	3.3
	Confidence Interval	(2-Sided) 95%; -2.9 to 8.7
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 43

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 88
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.9
	Confidence Interval	(2-Sided) 95%; -4.5 to 6.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 44

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 88
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.4
	Confidence Interval	(2-Sided) 95%; -4.6 to 6.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 45

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 92
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.3
	Confidence Interval	(2-Sided) 95%; -4.5 to 6.9
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 46

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 92
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.4
	Confidence Interval	(2-Sided) 95%; -4.5 to 6.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 47

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 96
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	2.8
	Confidence Interval	(2-Sided) 95%; -3.1 to 8.7
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 48

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 96
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.6
	Confidence Interval	(2-Sided) 95%; -4.7 to 7.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

17. Secondary Outcome

Title	Percentage of Subjects With BCVA of 73 Letters Read or More at Each Visit - Study Eye
Description	BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly (0-100 letters). A score of 65 to 70 letters represents a low to moderate visual acuity. Baseline was defined as the last measurement prior to first treatment. 95% CI for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.
Time Frame	Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96

Outcome Measure Data

Analysis Population Description

FAS-LOCF

Arm/Group Title	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Arm/Group Description	Single intravitreal (IVT) injection of brolucizumab ophthalmic solution administered as a 3 mg/50 microliter (μL) dose at Day 0, Week 4, and Week 8, followed by 1 injection every 8 weeks/1 injection every 12 weeks (q8w/q12w) maintenance regimen until study exit	Single IVT injection of brolucizumab ophthalmic solution administered as a 6 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Single IVT injection of aflibercept ophthalmic solution administered as a 2 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Measure Participants	358	360	360
Baseline	24.9	21.7	19.2
Week 4	34.6	33.3	33.9
Week 8	42.5	42.8	42.8
Week 12	45.3	43.9	45.8
Week 16	46.4	46.7	44.4
Week 20	46.4	46.9	48.1
Week 24	49.7	47.8	46.4
Week 28	48.9	49.7	46.9
Week 32	48.0	51.4	44.4
Week 36	47.8	50.6	48.3
Week 40	51.7	49.2	48.6
Week 44	49.7	50.0	50.3
Week 48	49.7	50.6	50.8
Week 52	48.6	50.6	49.2
Week 56	50.8	50.0	48.6
Week 60	52.0	48.1	49.2
Week 64	50.8	50.6	49.2
Week 68	50.6	48.3	46.7
Week 72	50.8	49.2	49.4
Week 76	52.2	49.2	46.1
Week 80	51.4	49.7	45.6
Week 84	50.6	47.2	45.3
Week 88	50.6	50.3	48.6
Week 92	51.7	49.4	45.8
Week 96	48.9	49.4	45.6

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 4
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-2.1
	Confidence Interval	(2-Sided) 95%; -7.7 to 3.5
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 4
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-2.7
	Confidence Interval	(2-Sided) 95%; -8.5 to 2.8
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 8
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-3.0
	Confidence Interval	(2-Sided) 95%; -8.9 to 2.6
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 8
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-2.1
	Confidence Interval	(2-Sided) 95%; -7.7 to 3.6
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 5

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 12
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-3.1
	Confidence Interval	(2-Sided) 95%; -8.9 to 2.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 6

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 12
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-4.0
	Confidence Interval	(2-Sided) 95%; -10.0 to 2.0
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 7

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 16
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.5
	Confidence Interval	(2-Sided) 95%; -6.3 to 5.5
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 8

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 16
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.1
	Confidence Interval	(2-Sided) 95%; -6.2 to 6.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 9

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 20
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-4.0
	Confidence Interval	(2-Sided) 95%; -10.4 to 2.0
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 10

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 20
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-3.4
	Confidence Interval	(2-Sided) 95%; -9.4 to 2.8
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 11

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 24
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.1
	Confidence Interval	(2-Sided) 95%; -4.6 to 6.9
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 12

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 24
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.6
	Confidence Interval	(2-Sided) 95%; -6.6 to 5.7
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 13

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 28
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.1
	Confidence Interval	(2-Sided) 95%; -6.5 to 5.7
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 14

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 28
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.1
	Confidence Interval	(2-Sided) 95%; -4.9 to 7.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 15

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 32
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.6
	Confidence Interval	(2-Sided) 95%; -3.9 to 7.5
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 16

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 32
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	5.1
	Confidence Interval	(2-Sided) 95%; -1.0 to 11.5
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 17

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 36
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-2.4
	Confidence Interval	(2-Sided) 95%; -8.5 to 3.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 18

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 36
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.4
	Confidence Interval	(2-Sided) 95%; -6.0 to 6.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 19

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 40
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.0
	Confidence Interval	(2-Sided) 95%; -5.2 to 6.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 20

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 40
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-1.2
	Confidence Interval	(2-Sided) 95%; -7.4 to 5.0
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 21

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 44
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-2.4
	Confidence Interval	(2-Sided) 95%; -8.8 to 3.5
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 22

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 44
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-2.2
	Confidence Interval	(2-Sided) 95%; -8.4 to 4.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 23

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 48
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-3.5
	Confidence Interval	(2-Sided) 95%; -9.5 to 2.3
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 24

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 48
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-2.4
	Confidence Interval	(2-Sided) 95%; -8.6 to 3.6
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 25

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 52
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-2.4
	Confidence Interval	(2-Sided) 95%; -8.8 to 3.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 26

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 52
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.5
	Confidence Interval	(2-Sided) 95%; -6.8 to 6.1
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 27

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 56
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.2
	Confidence Interval	(2-Sided) 95%; -5.9 to 6.1
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 28

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 56
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.6
	Confidence Interval	(2-Sided) 95%; -6.6 to 6.0
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 29

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 60
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.6
	Confidence Interval	(2-Sided) 95%; -5.7 to 6.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 30

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 60
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-3.0
	Confidence Interval	(2-Sided) 95%; -9.0 to 3.1
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 31

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 64
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.5
	Confidence Interval	(2-Sided) 95%; -7.2 to 5.5
	Parameter Dispersion	Type: Value:
	Estimation Comments

Statistical Analysis 32

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 64
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.6
	Confidence Interval	(2-Sided) 95%; -6.6 to 5.7
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 33

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 68
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	2.0
	Confidence Interval	(2-Sided) 95%; -4.3 to 8.3
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 34

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 68
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.1
	Confidence Interval	(2-Sided) 95%; -6.3 to 6.1
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 35

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 72
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.4
	Confidence Interval	(2-Sided) 95%; -7.2 to 5.6
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 36

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 72
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-2.1
	Confidence Interval	(2-Sided) 95%; -8.5 to 4.3
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 37

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 76
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	4.0
	Confidence Interval	(2-Sided) 95%; -2.4 to 10.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 38

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 76
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.2
	Confidence Interval	(2-Sided) 95%; -5.1 to 7.8
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 39

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 80
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	3.9
	Confidence Interval	(2-Sided) 95%; -2.5 to 9.6
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 40

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 80
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	2.4
	Confidence Interval	(2-Sided) 95%; -3.5 to 9.0
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 41

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 84
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	3.3
	Confidence Interval	(2-Sided) 95%; -3.0 to 9.0
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 42

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 84
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.2
	Confidence Interval	(2-Sided) 95%; -5.8 to 6.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 43

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 88
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.0
	Confidence Interval	(2-Sided) 95%; -6.6 to 6.5
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 44

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 88
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.1
	Confidence Interval	(2-Sided) 95%; -6.0 to 6.1
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 45

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 92
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	3.8
	Confidence Interval	(2-Sided) 95%; -2.8 to 9.5
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 46

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 92
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.8
	Confidence Interval	(2-Sided) 95%; -4.3 to 8.0
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 47

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 96
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.7
	Confidence Interval	(2-Sided) 95%; -4.7 to 7.8
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 48

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 96
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	2.3
	Confidence Interval	(2-Sided) 95%; -3.8 to 9.0
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

18. Secondary Outcome

Title	Change From Baseline in Central Subfield Thickness (CSFTtot) at Each Post-baseline Visit - Study Eye
Description	CSFTtot (the average retinal thickness of the circular area within 1 millimeter diameter around the foveal center) was assessed using Spectral-Domain Optical Coherence Tomography (SD-OCT), a non-invasive measurement which produces cross-sectional and 3-dimensional images of the eye. A negative change value indicates an improvement, while a positive change value indicates a worsening. One eye (study eye) contributed to the analysis.
Time Frame	Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96

Outcome Measure Data

Analysis Population Description

FAS - LOCF

Arm/Group Title	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Arm/Group Description	Single intravitreal (IVT) injection of brolucizumab ophthalmic solution administered as a 3 mg/50 microliter (μL) dose at Day 0, Week 4, and Week 8, followed by 1 injection every 8 weeks/1 injection every 12 weeks (q8w/q12w) maintenance regimen until study exit	Single IVT injection of brolucizumab ophthalmic solution administered as a 6 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Single IVT injection of aflibercept ophthalmic solution administered as a 2 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Measure Participants	358	360	360
Change from baseline at Week 4	-142.2 (130.54)	-150.9 (120.85)	-137.8 (120.62)
Change from baseline at Week 8	-163.7 (139.68)	-169.1 (132.62)	-154.3 (126.05)
Change from baseline at Week 12	-172.5 (142.82)	-177.6 (137.13)	-157.3 (125.86)
Change from baseline at Week 16	-151.4 (145.66)	-159.6 (133.91)	-135.3 (132.50)
Change from baseline at Week 20	-151.5 (142.70)	-153.8 (144.23)	-161.1 (128.75)
Change from baseline at Week 24	-160.4 (151.33)	-164.6 (141.67)	-138.9 (136.02)
Change from baseline at Week 28	-169.1 (147.81)	-169.7 (146.82)	-161.8 (133.79)
Change from baseline at Week 32	-153.9 (154.59)	-157.0 (144.46)	-137.5 (142.15)
Change from baseline at Week 36	-173.0 (150.80)	-175.3 (147.18)	-160.2 (137.94)
Change from baseline at Week 40	-164.3 (153.85)	-166.9 (141.94)	-141.1 (144.80)
Change from baseline at Week 44	-165.1 (151.34)	-167.4 (156.10)	-160.3 (139.14)
Change from baseline at Week 48	-165.3 (152.86)	-170.9 (142.48)	-145.6 (145.53)
Change from baseline at Week 52	-174.4 (149.06)	-173.8 (149.18)	-162.9 (141.57)
Change from baseline at Week 56	-161.7 (148.33)	-161.6 (149.26)	-145.5 (145.95)
Change from baseline at Week 60	-177.4 (150.58)	-171.3 (152.35)	-162.8 (143.92)
Change from baseline at Week 64	-170.8 (160.61)	-166.2 (148.96)	-147.6 (145.88)
Change from baseline at Week 68	-171.7 (149.54)	-169.8 (151.91)	-160.6 (150.34)
Change from baseline at Week 72	-173.0 (152.01)	-169.5 (149.17)	-146.8 (151.89)
Change from baseline at Week 76	-176.6 (154.87)	-172.9 (153.90)	-161.4 (147.50)
Change from baseline at Week 80	-168.4 (157.11)	-167.1 (152.62)	-147.2 (156.73)
Change from baseline at Week 84	-181.7 (152.44)	-173.9 (157.54)	-166.4 (151.94)
Change from baseline at Week 88	-174.3 (154.83)	-171.1 (152.31)	-150.9 (157.20)
Change from baseline at Week 92	-176.9 (154.63)	-174.1 (157.30)	-165.8 (150.35)
Change from baseline at Week 96	-177.8 (155.03)	-172.9 (156.38)	-150.7 (154.86)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 4
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-7.9
	Confidence Interval	(2-Sided) 95%; -24.2 to 8.4
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 8.30
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 4
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-16.5
	Confidence Interval	(2-Sided) 95%; -31.9 to -1.1
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 7.86
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 8
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-13.7
	Confidence Interval	(2-Sided) 95%; -30.4 to 3.0
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 8.51
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 8
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-19.0
	Confidence Interval	(2-Sided) 95%; -35.0 to -2.9
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 8.16
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 5

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 12
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-19.7
	Confidence Interval	(2-Sided) 95%; -36.3 to -3.1
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 8.45
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 6

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 12
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-24.5
	Confidence Interval	(2-Sided) 95%; -40.7 to -8.3
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 8.24
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 7

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 16
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.0159
	Comments	1-sided testing for superiority of brolucizumab 3 mg versus aflibercept 2 mg
	Method	ANOVA
	Comments	Analyzed using ANOVA model with baseline CSFT-total categories, age categories, and treatment as fixed effect factors.
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-19.9
	Confidence Interval	(2-Sided) 95%; -38.0 to -1.7
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 9.24
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 8

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 16
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.0008
	Comments	1-sided testing for superiority of brolucizumab 6 mg versus aflibercept 2 mg
	Method	ANOVA
	Comments	Analyzed using ANOVA model with baseline CSFT-total categories, age categories, and treatment as fixed effect factors.
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-27.8
	Confidence Interval	(2-Sided) 95%; -45.1 to -10.5
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 8.80
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 9

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 20
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	5.2
	Confidence Interval	(2-Sided) 95%; -11.8 to 22.3
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 8.69
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 10

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 20
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	3.2
	Confidence Interval	(2-Sided) 95%; -14.1 to 20.5
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 8.80
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 11

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 24
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-25.8
	Confidence Interval	(2-Sided) 95%; -44.3 to -7.2
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 9.44
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 12

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 24
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-29.6
	Confidence Interval	(2-Sided) 95%; -47.5 to -11.6
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 9.13
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 13

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 28
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-11.6
	Confidence Interval	(2-Sided) 95%; -29.2 to 5.9
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 8.96
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 14

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 28
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-12.1
	Confidence Interval	(2-Sided) 95%; -29.8 to 5.5
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 8.98
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 15

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 32
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-20.1
	Confidence Interval	(2-Sided) 95%; -39.6 to -0.7
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 9.91
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 16

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 32
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-23.2
	Confidence Interval	(2-Sided) 95%; -42.1 to -4.2
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 9.64
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 17

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 36
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-17.4
	Confidence Interval	(2-Sided) 95%; -35.5 to 0.7
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 9.24
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 18

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 36
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-19.6
	Confidence Interval	(2-Sided) 95%; -37.6 to -1.7
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 9.14
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 19

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 40
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-27.3
	Confidence Interval	(2-Sided) 95%; -46.6 to -8.0
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 9.83
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 20

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 40
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-29.5
	Confidence Interval	(2-Sided) 95%; -48.2 to -10.9
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 9.50
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 21

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 44
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-9.3
	Confidence Interval	(2-Sided) 95%; -27.5 to 8.9
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 9.27
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 22

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 44
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-11.4
	Confidence Interval	(2-Sided) 95%; -30.3 to 7.5
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 9.64
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 23

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 48
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.0075
	Comments	1-sided testing for superiority of brolucizumab 3 mg versus aflibercept 2 mg
	Method	ANOVA
	Comments	Analyzed using ANOVA model with baseline CSFT-total categories, age categories, and treatment as fixed effect factors.
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-23.9
	Confidence Interval	(2-Sided) 95%; -43.1 to -4.6
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 9.79
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 24

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 48
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.0012
	Comments	1-sided testing for superiority of brolucizumab 6 mg versus aflibercept 2 mg
	Method	ANOVA
	Comments	Analyzed using ANOVA model with baseline CSFT-total categories, age categories, and treatment as fixed effect factors.
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-29.0
	Confidence Interval	(2-Sided) 95%; -47.6 to -10.4
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 9.47
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 25

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 52
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-15.6
	Confidence Interval	(2-Sided) 95%; -33.6 to 2.4
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 9.17
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 26

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 52
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-15.1
	Confidence Interval	(2-Sided) 95%; -33.4 to 3.3
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 9.35
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 27

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 56
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-20.0
	Confidence Interval	(2-Sided) 95%; -38.9 to -1.1
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 9.62
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 28

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 56
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-20.0
	Confidence Interval	(2-Sided) 95%; -39.4 to -0.7
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 9.86
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 29

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 60
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-18.8
	Confidence Interval	(2-Sided) 95%; -37.0 to -0.5
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 9.30
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 30

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 60
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-12.7
	Confidence Interval	(2-Sided) 95%; -31.4 to 6.1
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 9.56
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 31

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 64
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-27.2
	Confidence Interval	(2-Sided) 95%; -46.7 to -7.6
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 9.96
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 32

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 64
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-22.5
	Confidence Interval	(2-Sided) 95%; -41.6 to -3.4
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 9.73
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 33

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 68
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-14.9
	Confidence Interval	(2-Sided) 95%; -33.8 to 3.9
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 9.60
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 34

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 68
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-13.2
	Confidence Interval	(2-Sided) 95%; -32.6 to 6.2
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 9.88
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 35

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 72
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-29.9
	Confidence Interval	(2-Sided) 95%; -49.3 to -10.5
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 9.89
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 36

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 72
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-26.4
	Confidence Interval	(2-Sided) 95%; -46.0 to -6.8
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 9.99
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 37

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 76
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-19.3
	Confidence Interval	(2-Sided) 95%; -38.2 to -0.4
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 9.62
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 38

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 76
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-15.7
	Confidence Interval	(2-Sided) 95%; -35.0 to 3.7
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 9.84
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 39

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 80
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-24.8
	Confidence Interval	(2-Sided) 95%; -45.0 to -4.5
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 10.34
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 40

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 80
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-23.7
	Confidence Interval	(2-Sided) 95%; -43.9 to -3.4
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 10.32
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 41

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 84
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-19.5
	Confidence Interval	(2-Sided) 95%; -38.4 to -0.5
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 9.65
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 42

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 84
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-11.8
	Confidence Interval	(2-Sided) 95%; -31.5 to 8.0
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 10.05
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 43

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 88
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-27.3
	Confidence Interval	(2-Sided) 95%; -47.3 to -7.4
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 10.16
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 44

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 88
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-24.2
	Confidence Interval	(2-Sided) 95%; -44.3 to -4.2
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 10.22
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 45

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 92
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-15.1
	Confidence Interval	(2-Sided) 95%; -34.2 to 3.9
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 9.70
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 46

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 92
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-12.5
	Confidence Interval	(2-Sided) 95%; -32.1 to 7.1
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 9.99
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 47

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 96
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-30.9
	Confidence Interval	(2-Sided) 95%; -50.6 to -11.3
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 10.00
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 48

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 96
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-26.0
	Confidence Interval	(2-Sided) 95%; -46.2 to -5.9
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 10.28
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

19. Secondary Outcome

Title	Average Change From Baseline in CSFTtot Over the Period Week 36 Through Week 48 - Study Eye
Description	CSFTtot (the average retinal thickness of the circular area within 1 millimeter diameter around the foveal center) was assessed using SD-OCT, a non-invasive measurement which produces cross-sectional and 3-dimensional images of the eye. A negative change value indicates an improvement, while a positive change value indicates a worsening. One eye (study eye) contributed to the analysis.
Time Frame	Baseline, Weeks 36, 40, 44, 48

Outcome Measure Data

Analysis Population Description

FAS - LOCF

Arm/Group Title	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Arm/Group Description	Single intravitreal (IVT) injection of brolucizumab ophthalmic solution administered as a 3 mg/50 microliter (μL) dose at Day 0, Week 4, and Week 8, followed by 1 injection every 8 weeks/1 injection every 12 weeks (q8w/q12w) maintenance regimen until study exit	Single IVT injection of brolucizumab ophthalmic solution administered as a 6 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Single IVT injection of aflibercept ophthalmic solution administered as a 2 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Measure Participants	358	360	360
Mean (Standard Deviation) [micrometers]	-166.9 (148.90)	-170.1 (143.48)	-151.8 (139.53)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.0183
	Comments	1-sided testing for superiority of brolucizumab 3 mg versus aflibercept 2 mg
	Method	ANOVA
	Comments	Analyzed using ANOVA model with baseline CSFT-total categories, age categories, and treatment as fixed effect factors.
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-19.5
	Confidence Interval	(2-Sided) 95%; -37.7 to -1.2
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 9.29
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.0075
	Comments	1-sided testing for superiority of brolucizumab 6 mg versus aflibercept 2 mg
	Method	ANOVA
	Comments	Analyzed using ANOVA model with baseline CSFT-total categories, age categories, and treatment as fixed effect factors.
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-22.4
	Confidence Interval	(2-Sided) 95%; -40.4 to -4.4
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 9.19
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

20. Secondary Outcome

Title	Average Change From Baseline in CSFTtot Over the Period Week 84 Through Week 96 - Study Eye
Description	CSFTtot (the average retinal thickness of the circular area within 1 millimeter diameter around the foveal center) was assessed using SD-OCT, a non-invasive measurement which produces cross-sectional and 3-dimensional images of the eye. A negative change value indicates an improvement, while a positive change value indicates a worsening. One eye (study eye) contributed to the analysis.
Time Frame	Baseline, Weeks 84, 88, 92, 96

Outcome Measure Data

Analysis Population Description

FAS - LOCF

Arm/Group Title	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Arm/Group Description	Single intravitreal (IVT) injection of brolucizumab ophthalmic solution administered as a 3 mg/50 microliter (μL) dose at Day 0, Week 4, and Week 8, followed by 1 injection every 8 weeks/1 injection every 12 weeks (q8w/q12w) maintenance regimen until study exit	Single IVT injection of brolucizumab ophthalmic solution administered as a 6 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Single IVT injection of aflibercept ophthalmic solution administered as a 2 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Measure Participants	358	360	360
Mean (Standard Deviation) [micrometers]	-177.7 (153.15)	-173.0 (154.47)	-158.4 (151.86)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-23.2
	Confidence Interval	(2-Sided) 95%; -42.4 to -4.1
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 9.76
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-18.6
	Confidence Interval	(2-Sided) 95%; -38.3 to 1.0
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 10.00
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

21. Secondary Outcome

Title	Average Change From Baseline in CSFTtot Over the Period Week 4 Through Week 48/96 - Study Eye
Description	CSFTtot (the average retinal thickness of the circular area within 1 millimeter diameter around the foveal center) was assessed using SD-OCT, a non-invasive measurement which produces cross-sectional and 3-dimensional images of the eye. A negative change value indicates an improvement, while a positive change value indicates a worsening. One eye (study eye) contributed to the analysis.
Time Frame	Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96

Outcome Measure Data

Analysis Population Description

FAS - LOCF

Arm/Group Title	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Arm/Group Description	Single intravitreal (IVT) injection of brolucizumab ophthalmic solution administered as a 3 mg/50 microliter (μL) dose at Day 0, Week 4, and Week 8, followed by 1 injection every 8 weeks/1 injection every 12 weeks (q8w/q12w) maintenance regimen until study exit	Single IVT injection of brolucizumab ophthalmic solution administered as a 6 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Single IVT injection of aflibercept ophthalmic solution administered as a 2 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Measure Participants	358	360	360
Change from baseline over the period Week 4 to 48	-161.0 (138.65)	-165.2 (135.36)	-149.3 (128.16)
Change from baseline over the period Week 4 to 96	-167.5 (143.12)	-167.8 (141.23)	-152.4 (135.75)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 4 to Week 48
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-16.0
	Confidence Interval	(2-Sided) 95%; -32.6 to 0.7
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 8.50
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 4 to Week 48
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-19.9
	Confidence Interval	(2-Sided) 95%; -36.5 to -3.3
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 8.45
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 4 to Week 96
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-18.9
	Confidence Interval	(2-Sided) 95%; -36.4 to -1.5
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 8.87
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 4 to Week 96
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-19.3
	Confidence Interval	(2-Sided) 95%; -36.9 to -1.8
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 8.93
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

22. Secondary Outcome

Title	Change From Baseline in Choroidal Neovascularization (CNV) Lesion Size at Week 12, Week 48, and Week 96 - Study Eye
Description	CNV lesion size (the area of new blood vessels in the choroid layer of the retina) size was measured using fluorescein angiography (FA). A negative change value indicates a reduction in lesion size, whereas a positive change value indicates an increase. An increase in CNV lesion size may indicate progression of the underlying disease. Only one eye (study eye) contributed to the analysis.
Time Frame	Baseline, Weeks 12, 48, 96

Outcome Measure Data

Analysis Population Description

FAS - LOCF. Number analyzed is the number of subjects with a value for both baseline and the specific post-baseline visit.

Arm/Group Title	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Arm/Group Description	Single intravitreal (IVT) injection of brolucizumab ophthalmic solution administered as a 3 mg/50 microliter (μL) dose at Day 0, Week 4, and Week 8, followed by 1 injection every 8 weeks/1 injection every 12 weeks (q8w/q12w) maintenance regimen until study exit	Single IVT injection of brolucizumab ophthalmic solution administered as a 6 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Single IVT injection of aflibercept ophthalmic solution administered as a 2 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Measure Participants	358	360	360
Change from baseline at Week 12	-3.3 (4.15)	-3.8 (3.89)	-3.2 (3.45)
Change from baseline at Week 48	-3.9 (4.59)	-4.0 (3.89)	-3.5 (4.03)
Change from baseline at Week 96	-3.9 (4.62)	-4.1 (4.07)	-3.5 (4.17)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 12
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-0.3
	Confidence Interval	(2-Sided) 95%; -0.8 to 0.1
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 0.23
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 12
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-0.6
	Confidence Interval	(2-Sided) 95%; -1.0 to -0.2
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 0.20
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 48
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-0.7
	Confidence Interval	(2-Sided) 95%; -1.1 to -0.2
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 0.24
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 48
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-0.5
	Confidence Interval	(2-Sided) 95%; -0.9 to 0.0
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 0.22
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 5

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 96
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-0.8
	Confidence Interval	(2-Sided) 95%; -1.3 to -0.3
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 0.26
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 6

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 96
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-0.7
	Confidence Interval	(2-Sided) 95%; -1.1 to -0.3
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 0.23
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

23. Secondary Outcome

Title	Change From Baseline in Central Subfield Neurosensory Retinal Thickness (CSFTns) at Each Post-baseline Visit - Study Eye
Description	Central subfield neurosensory retinal thickness was assessed using SD-OCT. A negative change value indicates an improvement, while a positive change value indicates a worsening. One eye (study eye) contributed to the analysis.
Time Frame	Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96

Outcome Measure Data

Analysis Population Description

FAS - LOCF

Arm/Group Title	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Arm/Group Description	Single intravitreal (IVT) injection of brolucizumab ophthalmic solution administered as a 3 mg/50 microliter (μL) dose at Day 0, Week 4, and Week 8, followed by 1 injection every 8 weeks/1 injection every 12 weeks (q8w/q12w) maintenance regimen until study exit	Single IVT injection of brolucizumab ophthalmic solution administered as a 6 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Single IVT injection of aflibercept ophthalmic solution administered as a 2 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Measure Participants	358	360	360
Change from baseline at Week 4	-56.3 (86.09)	-62.1 (88.73)	-61.0 (85.59)
Change from baseline at Week 8	-63.7 (87.09)	-66.3 (93.11)	-63.2 (88.65)
Change from baseline at Week 12	-67.0 (88.75)	-68.3 (94.14)	-63.7 (88.73)
Change from baseline at Week 16	-57.2 (91.00)	-61.1 (92.12)	-54.9 (91.55)
Change from baseline at Week 20	-58.6 (90.20)	-59.4 (91.78)	-65.5 (89.46)
Change from baseline at Week 24	-63.4 (91.06)	-65.0 (97.16)	-57.3 (91.89)
Change from baseline at Week 28	-67.9 (92.89)	-66.1 (98.08)	-67.2 (89.40)
Change from baseline at Week 32	-58.6 (93.16)	-60.4 (97.42)	-59.0 (90.77)
Change from baseline at Week 36	-67.4 (94.43)	-69.2 (100.29)	-67.1 (92.55)
Change from baseline at Week 40	-64.0 (93.94)	-67.0 (98.18)	-61.8 (90.60)
Change from baseline at Week 44	-65.2 (91.89)	-67.4 (99.33)	-67.5 (92.08)
Change from baseline at Week 48	-66.3 (95.57)	-66.4 (98.85)	-64.3 (92.86)
Change from baseline at Week 52	-70.4 (95.07)	-69.8 (100.94)	-69.5 (94.15)
Change from baseline at Week 56	-66.9 (95.57)	-65.0 (100.26)	-65.2 (93.33)
Change from baseline at Week 60	-73.0 (97.26)	-69.0 (102.69)	-69.9 (95.32)
Change from baseline at Week 64	-69.5 (97.07)	-68.3 (101.20)	-66.5 (94.25)
Change from baseline at Week 68	-69.5 (97.06)	-68.4 (101.24)	-69.0 (94.73)
Change from baseline at Week 72	-70.8 (96.61)	-68.4 (99.73)	-65.1 (94.75)
Change from baseline at Week 76	-70.0 (101.51)	-70.8 (102.45)	-69.1 (95.26)
Change from baseline at Week 80	-67.2 (102.52)	-68.2 (100.77)	-67.1 (92.06)
Change from baseline at Week 84	-72.7 (101.96)	-71.3 (102.48)	-69.6 (93.53)
Change from baseline at Week 88	-71.5 (98.52)	-69.3 (100.95)	-66.9 (93.64)
Change from baseline at Week 92	-71.6 (99.16)	-71.2 (104.98)	-70.3 (93.71)
Change from baseline at Week 96	-71.8 (99.15)	-70.4 (101.71)	-64.9 (94.21)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 4
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	7.1
	Confidence Interval	(2-Sided) 95%; -3.3 to 17.5
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 5.31
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 4
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	0.3
	Confidence Interval	(2-Sided) 95%; -10.2 to 10.9
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 5.37
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 8
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	2.1
	Confidence Interval	(2-Sided) 95%; -8.4 to 12.6
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 5.35
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 8
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-1.6
	Confidence Interval	(2-Sided) 95%; -12.5 to 9.2
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 5.52
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 5

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 12
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-0.6
	Confidence Interval	(2-Sided) 95%; -11.2 to 10.0
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 5.38
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 6

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 12
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-3.0
	Confidence Interval	(2-Sided) 95%; -13.9 to 7.9
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 5.55
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 7

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 16
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	0.2
	Confidence Interval	(2-Sided) 95%; -11.1 to 11.4
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 5.73
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 8

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 16
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-4.8
	Confidence Interval	(2-Sided) 95%; -16.1 to 6.5
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 5.76
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 9

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 20
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	9.3
	Confidence Interval	(2-Sided) 95%; -1.6 to 20.3
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 5.56
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 10

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 20
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	7.6
	Confidence Interval	(2-Sided) 95%; -3.4 to 18.5
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 5.58
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 11

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 24
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-3.6
	Confidence Interval	(2-Sided) 95%; -14.7 to 7.6
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 5.68
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 12

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 24
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-6.3
	Confidence Interval	(2-Sided) 95%; -17.9 to 5.3
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 5.92
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 13

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 28
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	2.1
	Confidence Interval	(2-Sided) 95%; -8.8 to 12.9
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 5.51
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 14

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 28
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	2.6
	Confidence Interval	(2-Sided) 95%; -8.7 to 13.8
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 5.73
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 15

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 32
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	2.9
	Confidence Interval	(2-Sided) 95%; -8.4 to 14.1
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 5.73
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 16

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 32
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-0.1
	Confidence Interval	(2-Sided) 95%; -11.7 to 11.5
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 5.92
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 17

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 36
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	2.4
	Confidence Interval	(2-Sided) 95%; -8.8 to 13.6
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 5.70
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 18

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 36
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-0.6
	Confidence Interval	(2-Sided) 95%; -12.2 to 10.9
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 5.89
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 19

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 40
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	0.5
	Confidence Interval	(2-Sided) 95%; -10.7 to 11.7
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 5.71
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 20

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 40
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-3.6
	Confidence Interval	(2-Sided) 95%; -15.0 to 7.8
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 5.83
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 21

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 44
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	4.9
	Confidence Interval	(2-Sided) 95%; -6.1 to 15.9
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 5.62
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 22

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 44
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	1.5
	Confidence Interval	(2-Sided) 95%; -10.0 to 13.1
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 5.87
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 23

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 48
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	0.8
	Confidence Interval	(2-Sided) 95%; -10.5 to 12.1
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 5.76
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 24

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 48
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-0.6
	Confidence Interval	(2-Sided) 95%; -12.2 to 11.1
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 5.93
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 25

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 52
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	1.9
	Confidence Interval	(2-Sided) 95%; -9.5 to 13.2
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 5.77
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 26

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 52
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	1.2
	Confidence Interval	(2-Sided) 95%; -10.6 to 13.1
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 6.04
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 27

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 56
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	0.9
	Confidence Interval	(2-Sided) 95%; -10.6 to 12.4
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 5.87
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 28

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 56
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	1.6
	Confidence Interval	(2-Sided) 95%; -10.4 to 13.5
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 6.08
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 29

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 60
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-0.4
	Confidence Interval	(2-Sided) 95%; -11.9 to 11.2
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 5.89
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 30

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 60
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	2.4
	Confidence Interval	(2-Sided) 95%; -9.7 to 14.6
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 6.17
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 31

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 64
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-0.2
	Confidence Interval	(2-Sided) 95%; -11.7 to 11.3
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 5.87
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 32

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 64
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-0.2
	Confidence Interval	(2-Sided) 95%; -12.2 to 11.7
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 6.09
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 33

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 68
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	2.3
	Confidence Interval	(2-Sided) 95%; -9.3 to 13.9
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 5.91
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 34

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 68
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	2.1
	Confidence Interval	(2-Sided) 95%; -9.8 to 14.0
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 6.08
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 35

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 72
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-2.9
	Confidence Interval	(2-Sided) 95%; -14.5 to 8.7
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 5.91
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 36

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 72
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-1.8
	Confidence Interval	(2-Sided) 95%; -13.7 to 10.1
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 6.06
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 37

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 76
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	1.8
	Confidence Interval	(2-Sided) 95%; -10.0 to 13.7
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 6.05
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 38

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 76
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-0.2
	Confidence Interval	(2-Sided) 95%; -12.2 to 11.8
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 6.13
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 39

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 80
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	2.8
	Confidence Interval	(2-Sided) 95%; -9.1 to 14.7
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 6.05
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 40

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 80
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	0.5
	Confidence Interval	(2-Sided) 95%; -11.3 to 12.3
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 6.01
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 41

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 84
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-0.2
	Confidence Interval	(2-Sided) 95%; -11.9 to 11.5
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 5.95
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 42

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 84
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-0.1
	Confidence Interval	(2-Sided) 95%; -12.0 to 11.7
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 6.04
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 43

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 88
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-1.7
	Confidence Interval	(2-Sided) 95%; -13.2 to 9.8
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 5.86
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 44

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 88
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-0.8
	Confidence Interval	(2-Sided) 95%; -12.6 to 11.0
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 6.00
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 45

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 92
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	1.7
	Confidence Interval	(2-Sided) 95%; -9.8 to 13.3
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 5.87
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 46

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 92
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	0.9
	Confidence Interval	(2-Sided) 95%; -11.1 to 12.8
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 6.09
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 47

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 96
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-4.0
	Confidence Interval	(2-Sided) 95%; -15.6 to 7.6
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 5.91
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 48

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 96
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-3.9
	Confidence Interval	(2-Sided) 95%; -15.8 to 8.0
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 6.07
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

24. Secondary Outcome

Title	Percentage of Subjects With Presence of Subretinal Fluid at Each Post-baseline Visit - Study Eye
Description	Subretinal fluid was assessed using SD-OCT and recorded as Present/Absent. The presence of subretinal fluid is an indicator of underlying disease. 95% CI for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.
Time Frame	Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96

Outcome Measure Data

Analysis Population Description

FAS - LOCF

Arm/Group Title	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Arm/Group Description	Single intravitreal (IVT) injection of brolucizumab ophthalmic solution administered as a 3 mg/50 microliter (μL) dose at Day 0, Week 4, and Week 8, followed by 1 injection every 8 weeks/1 injection every 12 weeks (q8w/q12w) maintenance regimen until study exit	Single IVT injection of brolucizumab ophthalmic solution administered as a 6 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Single IVT injection of aflibercept ophthalmic solution administered as a 2 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Measure Participants	358	360	360
Week 4	33.2	28.9	42.8
Week 8	19.0	12.8	27.5
Week 12	14.8	9.2	23.1
Week 16	26.0	16.9	36.7
Week 20	26.3	24.4	22.2
Week 24	23.5	13.1	36.4
Week 28	18.4	16.4	21.4
Week 32	28.2	23.9	36.1
Week 36	14.2	11.9	22.2
Week 40	21.5	16.1	27.5
Week 44	20.1	16.4	19.4
Week 48	18.2	14.4	30.0
Week 52	15.9	10.0	18.6
Week 56	20.4	18.1	27.5
Week 60	14.2	10.3	18.9
Week 64	18.7	14.4	26.4
Week 68	18.4	14.4	15.8
Week 72	16.2	11.4	23.9
Week 76	15.9	11.7	17.5
Week 80	17.6	12.2	23.9
Week 84	12.0	12.2	17.2
Week 88	17.3	11.7	23.3
Week 92	15.9	10.0	15.0
Week 96	15.6	10.3	21.4

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 4
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-9.4
	Confidence Interval	(2-Sided) 95%; -16.4 to -3.3
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 4
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-14.2
	Confidence Interval	(2-Sided) 95%; -21.3 to -7.3
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 8
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-8.4
	Confidence Interval	(2-Sided) 95%; -14.6 to -2.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 8
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-15.0
	Confidence Interval	(2-Sided) 95%; -20.9 to -9.5
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 5

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 12
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-8.1
	Confidence Interval	(2-Sided) 95%; -13.8 to -2.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 6

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 12
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-14.0
	Confidence Interval	(2-Sided) 95%; -18.9 to -8.7
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 7

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 16
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-10.4
	Confidence Interval	(2-Sided) 95%; -16.8 to -3.7
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 8

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 16
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-19.7
	Confidence Interval	(2-Sided) 95%; -25.8 to -13.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 9

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 20
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	4.1
	Confidence Interval	(2-Sided) 95%; -2.0 to 9.9
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 10

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 20
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	2.1
	Confidence Interval	(2-Sided) 95%; -4.3 to 7.9
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 11

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 24
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-12.7
	Confidence Interval	(2-Sided) 95%; -19.1 to -6.0
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 12

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 24
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-23.4
	Confidence Interval	(2-Sided) 95%; -29.7 to -17.6
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 13

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 28
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-2.8
	Confidence Interval	(2-Sided) 95%; -8.7 to 3.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 14

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 28
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-5.1
	Confidence Interval	(2-Sided) 95%; -11.2 to 0.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 15

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 32
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-7.7
	Confidence Interval	(2-Sided) 95%; -14.3 to -1.0
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 16

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 32
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-12.4
	Confidence Interval	(2-Sided) 95%; -19.3 to -6.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 17

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 36
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-7.8
	Confidence Interval	(2-Sided) 95%; -13.2 to -2.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 18

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 36
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-10.3
	Confidence Interval	(2-Sided) 95%; -15.9 to -4.9
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 19

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 40
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-5.6
	Confidence Interval	(2-Sided) 95%; -11.5 to 0.9
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 20

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 40
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-11.4
	Confidence Interval	(2-Sided) 95%; -17.7 to -5.6
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 21

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 44
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.9
	Confidence Interval	(2-Sided) 95%; -5.1 to 6.7
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 22

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 44
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-3.1
	Confidence Interval	(2-Sided) 95%; -8.7 to 2.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 23

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 48
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-11.6
	Confidence Interval	(2-Sided) 95%; -17.8 to -5.5
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 24

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 48
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-15.6
	Confidence Interval	(2-Sided) 95%; -21.2 to -9.7
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 25

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 52
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-2.6
	Confidence Interval	(2-Sided) 95%; -8.0 to 3.0
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 26

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 52
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-8.6
	Confidence Interval	(2-Sided) 95%; -13.7 to -3.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 27

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 56
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-6.9
	Confidence Interval	(2-Sided) 95%; -12.6 to -0.7
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 28

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 56
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-9.6
	Confidence Interval	(2-Sided) 95%; -16.0 to -3.8
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 29

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 60
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-4.5
	Confidence Interval	(2-Sided) 95%; -9.9 to 0.7
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 30

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 60
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-8.5
	Confidence Interval	(2-Sided) 95%; -13.9 to -3.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 31

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 64
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-7.4
	Confidence Interval	(2-Sided) 95%; -13.1 to -1.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 32

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 64
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-12.0
	Confidence Interval	(2-Sided) 95%; -17.8 to -6.0
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 33

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 68
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	2.7
	Confidence Interval	(2-Sided) 95%; -2.5 to 8.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 34

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 68
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-1.4
	Confidence Interval	(2-Sided) 95%; -6.7 to 3.7
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 35

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 72
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-7.5
	Confidence Interval	(2-Sided) 95%; -12.8 to -1.6
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 36

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 72
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-12.5
	Confidence Interval	(2-Sided) 95%; -18.2 to -7.0
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 37

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 76
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-1.4
	Confidence Interval	(2-Sided) 95%; -7.0 to 4.5
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 38

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 76
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-5.9
	Confidence Interval	(2-Sided) 95%; -11.4 to -0.7
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 39

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 80
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-6.1
	Confidence Interval	(2-Sided) 95%; -11.8 to -0.1
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 40

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 80
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-11.7
	Confidence Interval	(2-Sided) 95%; -17.0 to -6.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 41

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 84
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-5.1
	Confidence Interval	(2-Sided) 95%; -10.1 to 0.1
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 42

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 84
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-5.1
	Confidence Interval	(2-Sided) 95%; -10.0 to -0.0
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 43

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 88
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-5.7
	Confidence Interval	(2-Sided) 95%; -11.7 to 0.5
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 44

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 88
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-11.7
	Confidence Interval	(2-Sided) 95%; -17.3 to -6.3
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 45

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 92
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.1
	Confidence Interval	(2-Sided) 95%; -4.0 to 6.5
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 46

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 92
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-5.0
	Confidence Interval	(2-Sided) 95%; -9.7 to -0.3
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 47

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 96
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-5.5
	Confidence Interval	(2-Sided) 95%; -11.4 to -0.1
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 48

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 96
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-11.1
	Confidence Interval	(2-Sided) 95%; -16.4 to -6.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

25. Secondary Outcome

Title	Percentage of Subjects With Presence of Intraretinal Fluid at Each Post-baseline Visit - Study Eye
Description	Intraretinal fluid was assessed using SD-OCT and recorded as Present/Absent. The presence of intraretinal fluid is an indicator of underlying disease. 95% CI for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.
Time Frame	Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96

Outcome Measure Data

Analysis Population Description

FAS - LOCF

Arm/Group Title	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Arm/Group Description	Single intravitreal (IVT) injection of brolucizumab ophthalmic solution administered as a 3 mg/50 microliter (μL) dose at Day 0, Week 4, and Week 8, followed by 1 injection every 8 weeks/1 injection every 12 weeks (q8w/q12w) maintenance regimen until study exit	Single IVT injection of brolucizumab ophthalmic solution administered as a 6 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Single IVT injection of aflibercept ophthalmic solution administered as a 2 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Measure Participants	358	360	360
Week 4	20.4	23.9	22.2
Week 8	17.9	20.8	22.5
Week 12	14.2	17.2	16.9
Week 16	22.3	20.3	24.7
Week 20	25.7	25.0	15.0
Week 24	22.9	17.8	26.9
Week 28	21.8	18.1	18.9
Week 32	24.6	21.9	24.4
Week 36	17.9	16.4	18.6
Week 40	20.7	19.7	24.2
Week 44	21.5	18.6	16.7
Week 48	21.8	21.4	22.2
Week 52	18.4	16.9	15.0
Week 56	23.7	20.8	21.1
Week 60	15.1	15.8	16.4
Week 64	20.4	17.8	20.8
Week 68	19.8	16.4	14.2
Week 72	17.6	15.0	18.3
Week 76	17.3	15.6	14.2
Week 80	19.3	18.6	18.3
Week 84	16.8	14.2	14.4
Week 88	20.7	16.7	16.7
Week 92	17.6	14.4	13.6
Week 96	19.3	15.0	20.0

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 4
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-2.0
	Confidence Interval	(2-Sided) 95%; -7.9 to 3.6
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 4
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.7
	Confidence Interval	(2-Sided) 95%; -4.1 to 7.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 8
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-4.5
	Confidence Interval	(2-Sided) 95%; -10.0 to 1.3
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 8
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-1.5
	Confidence Interval	(2-Sided) 95%; -7.7 to 4.5
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 5

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 12
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-2.7
	Confidence Interval	(2-Sided) 95%; -7.6 to 2.3
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 6

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 12
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.3
	Confidence Interval	(2-Sided) 95%; -5.4 to 5.8
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 7

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 16
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-2.5
	Confidence Interval	(2-Sided) 95%; -8.3 to 3.6
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 8

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 16
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-4.3
	Confidence Interval	(2-Sided) 95%; -10.0 to 1.9
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 9

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 20
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	10.6
	Confidence Interval	(2-Sided) 95%; 5.0 to 16.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 10

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 20
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	10.0
	Confidence Interval	(2-Sided) 95%; 4.7 to 15.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 11

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 24
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-4.0
	Confidence Interval	(2-Sided) 95%; -9.8 to 1.7
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 12

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 24
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-9.0
	Confidence Interval	(2-Sided) 95%; -14.9 to -3.0
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 13

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 28
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	2.9
	Confidence Interval	(2-Sided) 95%; -2.1 to 8.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 14

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 28
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.8
	Confidence Interval	(2-Sided) 95%; -6.3 to 5.1
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 15

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 32
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.0
	Confidence Interval	(2-Sided) 95%; -5.8 to 6.1
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 16

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 32
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-2.5
	Confidence Interval	(2-Sided) 95%; -8.4 to 3.5
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 17

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 36
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-1.0
	Confidence Interval	(2-Sided) 95%; -6.4 to 4.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 18

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 36
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-2.3
	Confidence Interval	(2-Sided) 95%; -7.8 to 3.0
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 19

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 40
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-3.8
	Confidence Interval	(2-Sided) 95%; -9.6 to 1.7
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 20

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 40
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-4.6
	Confidence Interval	(2-Sided) 95%; -10.2 to 1.9
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 21

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 44
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	4.6
	Confidence Interval	(2-Sided) 95%; -1.0 to 9.9
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 22

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 44
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.9
	Confidence Interval	(2-Sided) 95%; -3.3 to 7.5
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 23

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 48
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.6
	Confidence Interval	(2-Sided) 95%; -6.2 to 5.1
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 24

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 48
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.8
	Confidence Interval	(2-Sided) 95%; -6.4 to 5.5
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 25

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 52
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	3.3
	Confidence Interval	(2-Sided) 95%; -2.2 to 8.7
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 26

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 52
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.9
	Confidence Interval	(2-Sided) 95%; -3.2 to 7.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 27

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 56
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	2.3
	Confidence Interval	(2-Sided) 95%; -3.5 to 8.1
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 28

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 56
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.3
	Confidence Interval	(2-Sided) 95%; -5.8 to 5.8
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 29

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 60
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-1.5
	Confidence Interval	(2-Sided) 95%; -6.6 to 3.8
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 30

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 60
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.5
	Confidence Interval	(2-Sided) 95%; -5.8 to 5.1
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 31

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 64
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.8
	Confidence Interval	(2-Sided) 95%; -6.4 to 5.1
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 32

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 64
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-3.0
	Confidence Interval	(2-Sided) 95%; -8.7 to 2.6
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 33

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 68
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	5.5
	Confidence Interval	(2-Sided) 95%; 0.3 to 10.7
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 34

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 68
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	2.2
	Confidence Interval	(2-Sided) 95%; -3.2 to 7.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 35

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 72
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.9
	Confidence Interval	(2-Sided) 95%; -6.1 to 4.7
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 36

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 72
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-3.4
	Confidence Interval	(2-Sided) 95%; -9.0 to 1.9
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 37

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 76
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	3.1
	Confidence Interval	(2-Sided) 95%; -1.9 to 8.1
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 38

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 76
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.3
	Confidence Interval	(2-Sided) 95%; -3.9 to 6.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 39

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 80
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.7
	Confidence Interval	(2-Sided) 95%; -4.7 to 6.6
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 40

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 80
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.2
	Confidence Interval	(2-Sided) 95%; -5.2 to 6.1
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 41

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 84
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	2.1
	Confidence Interval	(2-Sided) 95%; -3.3 to 7.3
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 42

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 84
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.3
	Confidence Interval	(2-Sided) 95%; -5.7 to 4.8
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 43

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 88
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	3.9
	Confidence Interval	(2-Sided) 95%; -1.7 to 9.7
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 44

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 88
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.1
	Confidence Interval	(2-Sided) 95%; -5.3 to 5.6
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 45

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 92
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	3.8
	Confidence Interval	(2-Sided) 95%; -1.3 to 8.9
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 46

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 92
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.9
	Confidence Interval	(2-Sided) 95%; -4.3 to 6.0
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 47

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 96
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.9
	Confidence Interval	(2-Sided) 95%; -6.4 to 5.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 48

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 96
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-4.9
	Confidence Interval	(2-Sided) 95%; -10.8 to 0.9
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

26. Secondary Outcome

Title	Percentage of Subjects With Presence of Sub-retinal Pigment Epithelium (RPE) Fluid at Each Post-baseline Visit - Study Eye
Description	Sub-RPE fluid was assessed using SD-OCT and recorded as Present/Absent. The presence of sub-RPE fluid is an indicator of underlying disease. 95% CI for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.
Time Frame	Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96

Outcome Measure Data

Analysis Population Description

FAS - LOCF

Arm/Group Title	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Arm/Group Description	Single intravitreal (IVT) injection of brolucizumab ophthalmic solution administered as a 3 mg/50 microliter (μL) dose at Day 0, Week 4, and Week 8, followed by 1 injection every 8 weeks/1 injection every 12 weeks (q8w/q12w) maintenance regimen until study exit	Single IVT injection of brolucizumab ophthalmic solution administered as a 6 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Single IVT injection of aflibercept ophthalmic solution administered as a 2 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Measure Participants	358	360	360
Week 4	25.4	24.2	29.2
Week 8	16.5	17.5	21.4
Week 12	13.7	14.2	21.1
Week 16	19.3	18.9	26.9
Week 20	19.8	20.6	17.8
Week 24	17.3	16.1	22.8
Week 28	18.7	15.6	18.3
Week 32	19.8	19.7	21.4
Week 36	12.8	13.1	18.1
Week 40	17.0	16.7	22.5
Week 44	16.2	13.9	18.1
Week 48	16.5	13.6	21.4
Week 52	12.8	12.8	13.9
Week 56	15.6	15.0	20.6
Week 60	12.6	13.1	15.3
Week 64	14.2	13.3	20.0
Week 68	13.7	14.2	15.3
Week 72	11.7	10.8	17.8
Week 76	12.0	12.5	13.3
Week 80	11.7	12.8	15.8
Week 84	11.5	11.7	16.7
Week 88	14.5	11.4	17.2
Week 92	12.6	10.3	13.1
Week 96	13.7	11.1	14.4

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 4
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-2.3
	Confidence Interval	(2-Sided) 95%; -7.7 to 3.6
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 4
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-5.7
	Confidence Interval	(2-Sided) 95%; -11.4 to 0.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 8
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-3.8
	Confidence Interval	(2-Sided) 95%; -9.3 to 1.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 8
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-4.4
	Confidence Interval	(2-Sided) 95%; -9.8 to 1.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 5

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 12
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-6.5
	Confidence Interval	(2-Sided) 95%; -11.5 to -1.5
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 6

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 12
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-7.6
	Confidence Interval	(2-Sided) 95%; -12.8 to -2.3
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 7

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 16
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-6.5
	Confidence Interval	(2-Sided) 95%; -11.8 to -1.1
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 8

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 16
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-8.6
	Confidence Interval	(2-Sided) 95%; -14.4 to -2.9
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 9

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 20
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	2.7
	Confidence Interval	(2-Sided) 95%; -2.8 to 8.3
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 10

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 20
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	2.1
	Confidence Interval	(2-Sided) 95%; -3.4 to 7.5
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 11

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 24
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-4.6
	Confidence Interval	(2-Sided) 95%; -9.7 to 0.9
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 12

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 24
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-7.1
	Confidence Interval	(2-Sided) 95%; -12.3 to -1.3
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 13

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 28
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.1
	Confidence Interval	(2-Sided) 95%; -4.2 to 6.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 14

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 28
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-3.2
	Confidence Interval	(2-Sided) 95%; -8.4 to 1.7
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 15

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 32
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.7
	Confidence Interval	(2-Sided) 95%; -6.2 to 5.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 16

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 32
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-2.4
	Confidence Interval	(2-Sided) 95%; -7.5 to 3.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 17

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 36
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-4.5
	Confidence Interval	(2-Sided) 95%; -9.5 to 0.7
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 18

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 36
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-5.4
	Confidence Interval	(2-Sided) 95%; -10.6 to -0.6
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 19

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 40
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-4.6
	Confidence Interval	(2-Sided) 95%; -10.2 to 1.3
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 20

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 40
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-6.3
	Confidence Interval	(2-Sided) 95%; -12.2 to -0.8
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 21

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 44
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-1.2
	Confidence Interval	(2-Sided) 95%; -6.6 to 4.3
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 22

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 44
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-4.7
	Confidence Interval	(2-Sided) 95%; -10.0 to 0.1
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 23

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 48
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-4.0
	Confidence Interval	(2-Sided) 95%; -9.4 to 1.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 24

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 48
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-8.1
	Confidence Interval	(2-Sided) 95%; -13.6 to -2.7
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 25

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 52
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.4
	Confidence Interval	(2-Sided) 95%; -5.1 to 4.5
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 26

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 52
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-1.6
	Confidence Interval	(2-Sided) 95%; -6.2 to 2.8
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 27

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 56
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-4.2
	Confidence Interval	(2-Sided) 95%; -9.4 to 1.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 28

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 56
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-6.2
	Confidence Interval	(2-Sided) 95%; -11.5 to -0.8
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 29

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 60
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-2.3
	Confidence Interval	(2-Sided) 95%; -7.3 to 3.0
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 30

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 60
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-2.7
	Confidence Interval	(2-Sided) 95%; -7.9 to 2.1
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 31

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 64
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-5.2
	Confidence Interval	(2-Sided) 95%; -10.5 to 0.7
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 32

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 64
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-7.1
	Confidence Interval	(2-Sided) 95%; -12.5 to -1.8
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 33

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 68
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-1.0
	Confidence Interval	(2-Sided) 95%; -6.0 to 4.0
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 34

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 68
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-1.3
	Confidence Interval	(2-Sided) 95%; -6.3 to 3.9
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 35

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 72
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-5.4
	Confidence Interval	(2-Sided) 95%; -10.1 to -0.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 36

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 72
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-7.3
	Confidence Interval	(2-Sided) 95%; -12.2 to -2.3
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 37

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 76
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.8
	Confidence Interval	(2-Sided) 95%; -5.2 to 4.3
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 38

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 76
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-1.0
	Confidence Interval	(2-Sided) 95%; -5.8 to 3.5
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 39

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 80
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-3.4
	Confidence Interval	(2-Sided) 95%; -8.4 to 1.8
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 40

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 80
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-3.3
	Confidence Interval	(2-Sided) 95%; -8.5 to 1.5
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 41

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 84
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-4.7
	Confidence Interval	(2-Sided) 95%; -9.8 to 0.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 42

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 84
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-5.4
	Confidence Interval	(2-Sided) 95%; -10.4 to -0.7
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 43

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 88
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-2.2
	Confidence Interval	(2-Sided) 95%; -7.4 to 3.0
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 44

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 88
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-6.0
	Confidence Interval	(2-Sided) 95%; -11.0 to -1.1
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 45

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 92
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.1
	Confidence Interval	(2-Sided) 95%; -4.9 to 5.1
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 46

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 92
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-3.0
	Confidence Interval	(2-Sided) 95%; -7.6 to 1.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 47

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 96
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.1
	Confidence Interval	(2-Sided) 95%; -5.3 to 5.1
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 48

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 96
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-3.8
	Confidence Interval	(2-Sided) 95%; -8.5 to 0.8
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

27. Secondary Outcome

Title	Percentage of Subjects With Presence of Subretinal and/or Intraretinal Fluid at Each Post-baseline Visit - Study Eye
Description	Subretinal fluid and intraretinal fluid were assessed using SD-OCT and recorded as Present/Absent. The presence of subretinal and/or intraretinal fluid is an indicator of underlying disease. 95% CI for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.
Time Frame	Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96

Outcome Measure Data

Analysis Population Description

FAS - LOCF

Arm/Group Title	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Arm/Group Description	Single intravitreal (IVT) injection of brolucizumab ophthalmic solution administered as a 3 mg/50 microliter (μL) dose at Day 0, Week 4, and Week 8, followed by 1 injection every 8 weeks/1 injection every 12 weeks (q8w/q12w) maintenance regimen until study exit	Single IVT injection of brolucizumab ophthalmic solution administered as a 6 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Single IVT injection of aflibercept ophthalmic solution administered as a 2 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Measure Participants	358	360	360
Week 4	47.8	47.2	54.7
Week 8	32.7	30.3	42.5
Week 12	26.0	24.2	34.4
Week 16	41.6	33.9	52.2
Week 20	45.3	44.4	33.3
Week 24	39.9	27.5	50.8
Week 28	36.9	31.4	35.3
Week 32	45.5	40.0	50.3
Week 36	28.8	25.6	34.7
Week 40	37.2	32.5	45.6
Week 44	38.3	32.2	32.2
Week 48	34.1	31.1	44.7
Week 52	30.7	24.7	29.7
Week 56	38.8	35.0	41.9
Week 60	27.1	23.6	30.8
Week 64	33.5	28.9	41.1
Week 68	34.1	29.2	26.9
Week 72	27.9	24.4	36.9
Week 76	28.8	25.3	28.6
Week 80	32.1	28.6	36.7
Week 84	26.3	23.9	28.3
Week 88	32.7	26.1	36.7
Week 92	29.9	22.8	25.8
Week 96	30.4	23.9	36.9

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 4
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-6.7
	Confidence Interval	(2-Sided) 95%; -14.1 to 0.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 4
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-7.4
	Confidence Interval	(2-Sided) 95%; -15.3 to -0.3
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 8
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-9.3
	Confidence Interval	(2-Sided) 95%; -16.6 to -2.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 8
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-12.1
	Confidence Interval	(2-Sided) 95%; -19.7 to -5.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 5

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 12
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-8.2
	Confidence Interval	(2-Sided) 95%; -14.8 to -1.6
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 6

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 12
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-10.2
	Confidence Interval	(2-Sided) 95%; -17.4 to -3.9
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 7

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 16
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.0030
	Comments	1-sided testing for superiority of brolucizumab 3 mg versus aflibercept 2 mg
	Method	Regression, Logistic
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-10.2
	Confidence Interval	(2-Sided) 95%; -17.3 to -2.5
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 8

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 16
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	<0.0001
	Comments	1-sided testing for superiority of brolucizumab 6 mg versus aflibercept 2 mg
	Method	Regression, Logistic
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-18.2
	Confidence Interval	(2-Sided) 95%; -25.3 to -10.9
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 9

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 20
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	12.0
	Confidence Interval	(2-Sided) 95%; 5.2 to 19.0
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 10

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 20
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	11.1
	Confidence Interval	(2-Sided) 95%; 3.8 to 18.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 11

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 24
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-10.6
	Confidence Interval	(2-Sided) 95%; -17.7 to -3.1
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 12

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 24
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-23.2
	Confidence Interval	(2-Sided) 95%; -30.5 to -16.1
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 13

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 28
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.7
	Confidence Interval	(2-Sided) 95%; -4.8 to 9.0
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 14

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 28
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-3.9
	Confidence Interval	(2-Sided) 95%; -11.8 to 2.5
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 15

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 32
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-4.5
	Confidence Interval	(2-Sided) 95%; -12.0 to 3.1
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 16

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 32
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-10.3
	Confidence Interval	(2-Sided) 95%; -18.0 to -3.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 17

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 36
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-5.9
	Confidence Interval	(2-Sided) 95%; -12.5 to 0.8
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 18

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 36
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-9.2
	Confidence Interval	(2-Sided) 95%; -16.2 to -2.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 19

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 40
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-8.2
	Confidence Interval	(2-Sided) 95%; -15.7 to -0.6
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 20

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 40
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-13.0
	Confidence Interval	(2-Sided) 95%; -20.5 to -5.5
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 21

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 44
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	6.0
	Confidence Interval	(2-Sided) 95%; -0.8 to 13.0
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 22

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 44
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-0.1
	Confidence Interval	(2-Sided) 95%; -7.5 to 6.6
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 23

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 48
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.0020
	Comments	1-sided testing for superiority of brolucizumab 3 mg versus aflibercept 2 mg
	Method	Regression, Logistic
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-10.5
	Confidence Interval	(2-Sided) 95%; -17.4 to -3.3
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 24

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 48
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.0001
	Comments	1-sided testing for superiority of brolucizumab 6 mg versus aflibercept 2 mg
	Method	Regression, Logistic
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-13.5
	Confidence Interval	(2-Sided) 95%; -20.7 to -6.1
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 25

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 52
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	1.0
	Confidence Interval	(2-Sided) 95%; -5.4 to 8.1
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 26

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 52
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-4.9
	Confidence Interval	(2-Sided) 95%; -11.8 to 1.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 27

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 56
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-3.2
	Confidence Interval	(2-Sided) 95%; -10.3 to 3.7
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 28

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 56
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-6.9
	Confidence Interval	(2-Sided) 95%; -14.1 to 0.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 29

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 60
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-3.8
	Confidence Interval	(2-Sided) 95%; -10.1 to 3.3
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 30

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 60
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-7.1
	Confidence Interval	(2-Sided) 95%; -14.0 to -0.6
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 31

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 64
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-7.6
	Confidence Interval	(2-Sided) 95%; -14.7 to -0.1
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 32

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 64
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-12.1
	Confidence Interval	(2-Sided) 95%; -19.5 to -5.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 33

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 68
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	7.2
	Confidence Interval	(2-Sided) 95%; 0.3 to 13.5
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 34

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 68
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	2.2
	Confidence Interval	(2-Sided) 95%; -4.9 to 8.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 35

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 72
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-8.9
	Confidence Interval	(2-Sided) 95%; -15.7 to -1.7
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 36

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 72
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-12.5
	Confidence Interval	(2-Sided) 95%; -19.8 to -5.6
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 37

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 76
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	0.3
	Confidence Interval	(2-Sided) 95%; -5.9 to 7.2
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 38

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 76
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-3.4
	Confidence Interval	(2-Sided) 95%; -9.8 to 2.6
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 39

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 80
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-4.4
	Confidence Interval	(2-Sided) 95%; -11.2 to 2.5
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 40

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 80
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-8.1
	Confidence Interval	(2-Sided) 95%; -15.3 to -1.0
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 41

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 84
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-2.1
	Confidence Interval	(2-Sided) 95%; -8.9 to 4.6
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 42

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 84
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-4.5
	Confidence Interval	(2-Sided) 95%; -11.2 to 1.7
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 43

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 88
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-3.8
	Confidence Interval	(2-Sided) 95%; -10.8 to 3.7
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 44

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 88
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-10.3
	Confidence Interval	(2-Sided) 95%; -17.3 to -3.5
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 45

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 92
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	4.1
	Confidence Interval	(2-Sided) 95%; -2.3 to 11.0
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 46

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 92
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-3.0
	Confidence Interval	(2-Sided) 95%; -9.8 to 2.6
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 47

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 96
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-6.4
	Confidence Interval	(2-Sided) 95%; -13.2 to 0.7
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.

Statistical Analysis 48

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 96
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Difference in proportions
	Estimated Value	-12.9
	Confidence Interval	(2-Sided) 95%; -19.7 to -6.6
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

28. Secondary Outcome

Title	Number of Subjects With Subretinal Fluid (SRF) and/or Intraretinal Fluid (IRF) Present Between Week 36 to Week 48, Reported by Number of Visits
Description	Subretinal fluid and intraretinal fluid were assessed using SD-OCT and recorded as Present/Absent. The presence of subretinal and/or intraretinal fluid is an indicator of underlying disease. One eye (study eye) contributed to the analysis. For each subject, the number of visits with SRF and/or IRF fluid is analyzed.
Time Frame	Weeks 36, 40, 44, 48

Outcome Measure Data

Analysis Population Description

FAS - LOCF

Arm/Group Title	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Arm/Group Description	Single intravitreal (IVT) injection of brolucizumab ophthalmic solution administered as a 3 mg/50 microliter (μL) dose at Day 0, Week 4, and Week 8, followed by 1 injection every 8 weeks/1 injection every 12 weeks (q8w/q12w) maintenance regimen until study exit	Single IVT injection of brolucizumab ophthalmic solution administered as a 6 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Single IVT injection of aflibercept ophthalmic solution administered as a 2 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Measure Participants	358	360	360
0 Visits	154	171	153
1 Visit	67	73	48
2 Visits	47	39	39
3 Visits	26	22	40
4 Visits	64	55	60

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.0574
	Comments	1-sided testing for superiority of brolucizumab 3 mg versus aflibercept 2 mg
	Method	Cochran-Mantel-Haenszel
	Comments	CMH-test row mean score (scores=table) stratified by age categories (<75, ≥75 years) and baseline fluid status)

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.0012
	Comments	1-sided testing for superiority of brolucizumab 6 mg versus aflibercept 2 mg
	Method	Cochran-Mantel-Haenszel
	Comments	CMH-test row mean score (scores=table) stratified by age categories (<75, ≥75 years) and baseline fluid status)

29. Secondary Outcome

Title	Percentage of Subjects With Disease Activity Present (q8 Treatment Need = "Yes") at Week 16 - Study Eye
Description	A disease activity assessment (DAA) was performed to identify q8 treatment need. 95% CI for binomial proportions is based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.
Time Frame	Week 16

Outcome Measure Data

Analysis Population Description

FAS - 'efficacy/safety' approach. Censored data attributable to lack of efficacy and/or safety are imputed with q8w need = Yes at the next disease activity assessment visit.

Arm/Group Title	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Arm/Group Description	Single intravitreal (IVT) injection of brolucizumab ophthalmic solution administered as a 3 mg/50 microliter (μL) dose at Day 0, Week 4, and Week 8, followed by 1 injection every 8 weeks/1 injection every 12 weeks (q8w/q12w) maintenance regimen until study exit	Single IVT injection of brolucizumab ophthalmic solution administered as a 6 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Single IVT injection of aflibercept ophthalmic solution administered as a 2 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Measure Participants	353	346	344
Number (95% Confidence Interval) [percentage of subjects]	28.0	24.0	34.6

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.0331
	Comments	1-sided testing for superiority of brolucizumab 3 mg versus aflibercept 2 mg
	Method	Regression, Logistic
	Comments
Method of Estimation	Estimation Parameter	difference in proportions
	Estimated Value	-6.5
	Confidence Interval	(2-Sided) 95%; -13.2 to 0.3
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for age categories (<75, >=75 years) and treatment as fixed effect factors. 95% CI for the treatment difference estimated using bootstrap method.

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.0013
	Comments	1-sided testing for superiority of brolucizumab 6 mg versus aflibercept 2 mg
	Method	Regression, Logistic
	Comments
Method of Estimation	Estimation Parameter	difference in proportions
	Estimated Value	-10.5
	Confidence Interval	(2-Sided) 95%; -17.1 to -3.5
	Parameter Dispersion	Type: Value:
	Estimation Comments	Statistical model used logistic regression adjusting for age categories (<75, >=75 years) and treatment as fixed effect factors. 95% CI for the treatment difference estimated using bootstrap method.

30. Secondary Outcome

Title	Change From Baseline in Visual Function Questionnaire (VFQ-25) Composite Score at Week 24, Week 48, Week 72, and Week 96
Description	The National Eye Institute Visual Function Questionnaire-25 (VFQ-25) is a validated questionnaire that collects 25 vision-targeted responses from age-related macular degeneration (AMD) subjects. The 25 questions pertain to global vision rating (1), difficulty with near vision activities (3), difficulty with distance vision activities (3), limitations in social functioning due to vision (2), role limitations due to vision (2), dependency on others due to vision (3), mental health symptoms due to vision (4), driving difficulties (3), limitations with peripheral (1) and color vision (1), and ocular pain (2). Each response is converted to a 0 to 100 sub-scale, with the lowest and highest possible scores set at 0 and 100 points, respectively. The overall composite score (0 to 100) is obtained by averaging the 25 sub-scale scores. A high score represents better functioning.
Time Frame	Baseline, Weeks 24, 48, 72, 96

Outcome Measure Data

Analysis Population Description

FAS - Observed. Number analyzed is the number of subjects with a value for both baseline and the specific post-baseline visit.

Arm/Group Title	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Arm/Group Description	Single intravitreal (IVT) injection of brolucizumab ophthalmic solution administered as a 3 mg/50 microliter (μL) dose at Day 0, Week 4, and Week 8, followed by 1 injection every 8 weeks/1 injection every 12 weeks (q8w/q12w) maintenance regimen until study exit	Single IVT injection of brolucizumab ophthalmic solution administered as a 6 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Single IVT injection of aflibercept ophthalmic solution administered as a 2 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Measure Participants	358	360	360
Change from baseline at Week 24	4.4 (10.49)	4.0 (12.20)	3.5 (9.97)
Change from baseline at Week 48	4.3 (11.44)	4.1 (12.58)	4.5 (10.64)
Change from baseline at Week 72	4.4 (12.19)	3.9 (12.53)	4.0 (12.05)
Change from baseline at Week 96	3.8 (13.53)	3.8 (13.50)	2.8 (13.28)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 24
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least squares mean difference
	Estimated Value	0.90
	Confidence Interval	(2-Sided) 95%; -0.5 to 2.3
	Parameter Dispersion	Type: Value:
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 24
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least squares mean difference
	Estimated Value	0.63
	Confidence Interval	(2-Sided) 95%; -0.9 to 2.1
	Parameter Dispersion	Type: Value:
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 48
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least squares mean difference
	Estimated Value	-0.20
	Confidence Interval	(2-Sided) 95%; -1.8 to 1.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 48
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least squares mean difference
	Estimated Value	-0.26
	Confidence Interval	(2-Sided) 95%; -1.9 to 1.4
	Parameter Dispersion	Type: Value:
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 5

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 72
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least squares mean difference
	Estimated Value	0.18
	Confidence Interval	(2-Sided) 95%; -1.6 to 1.9
	Parameter Dispersion	Type: Value:
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 6

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 72
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least squares mean difference
	Estimated Value	-0.12
	Confidence Interval	(2-Sided) 95%; -1.9 to 1.7
	Parameter Dispersion	Type: Value:
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

Statistical Analysis 7

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 3 mg, Aflibercept 2 mg
	Comments	Week 96
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least squares mean difference
	Estimated Value	0.75
	Confidence Interval	(2-Sided) 95%; -1.2 to 2.7
	Parameter Dispersion	Type: Value:
	Estimation Comments	Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)

Statistical Analysis 8

Statistical Analysis Overview	Comparison Group Selection	Brolucizumab 6 mg, Aflibercept 2 mg
	Comments	Week 96
	Type of Statistical Test	Other
	Comments	Treatment difference
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Least squares mean difference
	Estimated Value	1.05
	Confidence Interval	(2-Sided) 95%; -0.9 to 3.0
	Parameter Dispersion	Type: Value:
	Estimation Comments	Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

31. Secondary Outcome

Title	Percentage of Subjects With Induced or Boosted Anti-drug Antibody (ADA) Status at Week 48 (Brolucizumab Only)
Description	Serum samples were collected and assessed for anti-drug antibody status. Subjects were categorized as ADA negative when one of the following was met: ADA negative at all time points (predose and postdose); ADA negative at predose and no titer values above 10 at all other time points; or ADA titer of 10 at predose but negative at all other time points. ADA induced was defined as ADA negative at predose with postdose titer value greater than or equal to a titer of 30 at any timepoint. ADA boosted was defined as ADA positive at predose with postdose titer values that increased by at least two dilutions (9-fold) from their respective predose value at any time point. Hypothesis testing not pre-specified.
Time Frame	Week 48

Outcome Measure Data

Analysis Population Description

Safety Analysis Set - Observed. All randomized subjects who received at least 1 intravitreal injection.

Arm/Group Title	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Arm/Group Description	Single intravitreal (IVT) injection of brolucizumab ophthalmic solution administered as a 3 mg/50 microliter (μL) dose at Day 0, Week 4, and Week 8, followed by 1 injection every 8 weeks/1 injection every 12 weeks (q8w/q12w) maintenance regimen until study exit	Single IVT injection of brolucizumab ophthalmic solution administered as a 6 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Single IVT injection of aflibercept ophthalmic solution administered as a 2 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Measure Participants	356	353	348
Number [percentage of subjects]	25.6	20.4	65.8

32. Secondary Outcome

Title	Percentage of Subjects With Intraretinal Hemorrhage (Central Subfield) Present at the Visit While Absent at Baseline at Each Treatment - Study Eye
Description	Intraretinal hemorrhage was assessed using SD-OCT and recorded as Present/Absent. The presence of intraretinal hemorrhage is an indicator of underlying disease. 95% CI for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis. Hypothesis testing not pre-specified.
Time Frame	Baseline, Weeks 12, 48, 96

Outcome Measure Data

Analysis Population Description

FAS with non-missing values. Number analyzed is the number of subjects with a value for both baseline and the specific post-baseline visit.

Arm/Group Title	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Arm/Group Description	Single intravitreal (IVT) injection of brolucizumab ophthalmic solution administered as a 3 mg/50 microliter (μL) dose at Day 0, Week 4, and Week 8, followed by 1 injection every 8 weeks/1 injection every 12 weeks (q8w/q12w) maintenance regimen until study exit	Single IVT injection of brolucizumab ophthalmic solution administered as a 6 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Single IVT injection of aflibercept ophthalmic solution administered as a 2 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Measure Participants	358	360	360
Week 12	0.0	0.3	0.9
Week 48	0.0	0.0	0.0
Week 96	0.3	0.0	0.0

33. Secondary Outcome

Title	Percentage of Subjects With Subretinal Hemorrhage (Central Subfield) Present at the Visit While Absent at Baseline at Each Treatment - Study Eye
Description	Subretinal hemorrhage was assessed using SD-OCT and recorded as Present/Absent. The presence of subretinal hemorrhage is an indicator of underlying disease. 95% CI for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis. Hypothesis testing not pre-specified.
Time Frame	Baseline, Weeks 12, 48, 96

Outcome Measure Data

Analysis Population Description

FAS with non-missing values. Number analyzed is the number of subjects with a value for both baseline and the specific post-baseline visit.

Arm/Group Title	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Arm/Group Description	Single intravitreal (IVT) injection of brolucizumab ophthalmic solution administered as a 3 mg/50 microliter (μL) dose at Day 0, Week 4, and Week 8, followed by 1 injection every 8 weeks/1 injection every 12 weeks (q8w/q12w) maintenance regimen until study exit	Single IVT injection of brolucizumab ophthalmic solution administered as a 6 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Single IVT injection of aflibercept ophthalmic solution administered as a 2 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Measure Participants	358	360	360
Week 12	1.6	2.4	0.7
Week 48	1.8	0.4	2.6
Week 96	0.7	0.8	1.6

Adverse Events

Time Frame	First treatment through study completion, an average of 96 weeks
Adverse Event Reporting Description	Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Arm/Group Title	Brolucizumab 3mg		Brolucizumab 6mg		Aflibercept 2mg
Arm/Group Description	All subjects exposed to brolucizumab ophthalmic solution administered as a 3 mg/50 microliter (μL) dose		All subjects exposed to brolucizumab ophthalmic solution administered as a 6 mg/50 microliter (μL) dose		All subjects exposed to aflibercept ophthalmic solution administered as a 2 mg/50 μL dose
All Cause Mortality
	Brolucizumab 3mg		Brolucizumab 6mg		Aflibercept 2mg
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	9/358 (2.5%)		8/360 (2.2%)		12/360 (3.3%)
Serious Adverse Events
	Brolucizumab 3mg		Brolucizumab 6mg		Aflibercept 2mg
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	94/358 (26.3%)		95/360 (26.4%)		114/360 (31.7%)
Blood and lymphatic system disorders
Anaemia	0/358 (0%)		1/360 (0.3%)		1/360 (0.3%)
Anaemia megaloblastic	0/358 (0%)		1/360 (0.3%)		0/360 (0%)
Coagulopathy	0/358 (0%)		1/360 (0.3%)		0/360 (0%)
Cardiac disorders
Acute left ventricular failure	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Acute myocardial infarction	2/358 (0.6%)		1/360 (0.3%)		1/360 (0.3%)
Angina pectoris	0/358 (0%)		1/360 (0.3%)		1/360 (0.3%)
Angina unstable	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Aortic valve incompetence	1/358 (0.3%)		0/360 (0%)		0/360 (0%)
Arrhythmia	0/358 (0%)		2/360 (0.6%)		1/360 (0.3%)
Atrial fibrillation	4/358 (1.1%)		4/360 (1.1%)		2/360 (0.6%)
Atrial flutter	0/358 (0%)		1/360 (0.3%)		0/360 (0%)
Atrioventricular block	0/358 (0%)		1/360 (0.3%)		0/360 (0%)
Atrioventricular block second degree	0/358 (0%)		1/360 (0.3%)		0/360 (0%)
Cardiac arrest	1/358 (0.3%)		1/360 (0.3%)		2/360 (0.6%)
Cardiac disorder	0/358 (0%)		1/360 (0.3%)		0/360 (0%)
Cardiac failure	1/358 (0.3%)		0/360 (0%)		2/360 (0.6%)
Cardiac failure congestive	4/358 (1.1%)		6/360 (1.7%)		4/360 (1.1%)
Cardiac ventricular thrombosis	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Cardio-respiratory arrest	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Cardiogenic shock	1/358 (0.3%)		0/360 (0%)		0/360 (0%)
Coronary artery disease	6/358 (1.7%)		1/360 (0.3%)		3/360 (0.8%)
Coronary artery occlusion	0/358 (0%)		1/360 (0.3%)		0/360 (0%)
Left ventricular failure	1/358 (0.3%)		0/360 (0%)		1/360 (0.3%)
Mitral valve incompetence	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Myocardial infarction	1/358 (0.3%)		2/360 (0.6%)		3/360 (0.8%)
Palpitations	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Pericardial effusion	1/358 (0.3%)		0/360 (0%)		0/360 (0%)
Ventricular tachycardia	1/358 (0.3%)		0/360 (0%)		0/360 (0%)
Congenital, familial and genetic disorders
Endocardial fibroelastosis	1/358 (0.3%)		0/360 (0%)		0/360 (0%)
Eye disorders
Cataract - Fellow eye	0/358 (0%)		1/360 (0.3%)		0/360 (0%)
Cataract - Study eye	0/358 (0%)		1/360 (0.3%)		0/360 (0%)
Cataract subcapsular - Study eye	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Glaucoma - Study eye	1/358 (0.3%)		0/360 (0%)		0/360 (0%)
Macular hole - Study eye	0/358 (0%)		1/360 (0.3%)		1/360 (0.3%)
Neovascular age-related macular degeneration - Fellow eye	0/358 (0%)		1/360 (0.3%)		0/360 (0%)
Retinal artery occlusion - Study eye	3/358 (0.8%)		0/360 (0%)		0/360 (0%)
Retinal artery thrombosis - Study eye	0/358 (0%)		1/360 (0.3%)		0/360 (0%)
Retinal depigmentation - Study eye	0/358 (0%)		1/360 (0.3%)		0/360 (0%)
Retinal detachment - Study eye	1/358 (0.3%)		1/360 (0.3%)		1/360 (0.3%)
Retinal haemorrhage - Fellow eye	0/358 (0%)		1/360 (0.3%)		0/360 (0%)
Retinopathy proliferative - Study eye	0/358 (0%)		1/360 (0.3%)		0/360 (0%)
Uveitis - Study eye	1/358 (0.3%)		2/360 (0.6%)		0/360 (0%)
Visual acuity reduced - Study eye	0/358 (0%)		1/360 (0.3%)		2/360 (0.6%)
Vitritis - Study eye	0/358 (0%)		1/360 (0.3%)		0/360 (0%)
Gastrointestinal disorders
Abdominal hernia	0/358 (0%)		0/360 (0%)		2/360 (0.6%)
Abdominal pain	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Acute abdomen	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Colitis ischaemic	1/358 (0.3%)		0/360 (0%)		1/360 (0.3%)
Colitis microscopic	1/358 (0.3%)		0/360 (0%)		0/360 (0%)
Constipation	0/358 (0%)		2/360 (0.6%)		0/360 (0%)
Diverticulum intestinal haemorrhagic	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Duodenal ulcer haemorrhage	1/358 (0.3%)		0/360 (0%)		0/360 (0%)
Gastrointestinal haemorrhage	1/358 (0.3%)		0/360 (0%)		0/360 (0%)
Haemorrhoids	1/358 (0.3%)		0/360 (0%)		0/360 (0%)
Hiatus hernia	1/358 (0.3%)		0/360 (0%)		0/360 (0%)
Inguinal hernia	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Intestinal obstruction	1/358 (0.3%)		0/360 (0%)		3/360 (0.8%)
Intestinal perforation	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Large intestinal haemorrhage	1/358 (0.3%)		0/360 (0%)		0/360 (0%)
Large intestine polyp	0/358 (0%)		2/360 (0.6%)		1/360 (0.3%)
Lower gastrointestinal haemorrhage	1/358 (0.3%)		0/360 (0%)		0/360 (0%)
Nausea	1/358 (0.3%)		0/360 (0%)		0/360 (0%)
Oesophageal stenosis	1/358 (0.3%)		0/360 (0%)		0/360 (0%)
Pancreatitis	0/358 (0%)		1/360 (0.3%)		0/360 (0%)
Rectal haemorrhage	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Rectal polyp	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Retroperitoneal haemorrhage	0/358 (0%)		1/360 (0.3%)		0/360 (0%)
Small intestinal perforation	0/358 (0%)		1/360 (0.3%)		0/360 (0%)
Umbilical hernia	0/358 (0%)		1/360 (0.3%)		0/360 (0%)
Vomiting	1/358 (0.3%)		1/360 (0.3%)		0/360 (0%)
General disorders
Asthenia	1/358 (0.3%)		1/360 (0.3%)		0/360 (0%)
Chest pain	1/358 (0.3%)		0/360 (0%)		1/360 (0.3%)
Death	1/358 (0.3%)		0/360 (0%)		2/360 (0.6%)
Mass	1/358 (0.3%)		0/360 (0%)		0/360 (0%)
Non-cardiac chest pain	1/358 (0.3%)		1/360 (0.3%)		3/360 (0.8%)
Pyrexia	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Hepatobiliary disorders
Bile duct obstruction	0/358 (0%)		1/360 (0.3%)		0/360 (0%)
Bile duct stone	2/358 (0.6%)		0/360 (0%)		0/360 (0%)
Cholangitis	1/358 (0.3%)		0/360 (0%)		0/360 (0%)
Cholecystitis	1/358 (0.3%)		0/360 (0%)		0/360 (0%)
Cholecystitis acute	1/358 (0.3%)		0/360 (0%)		1/360 (0.3%)
Cholelithiasis	4/358 (1.1%)		1/360 (0.3%)		2/360 (0.6%)
Hepatic failure	0/358 (0%)		1/360 (0.3%)		0/360 (0%)
Hepatitis acute	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Immune system disorders
Anaphylactic reaction	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Infections and infestations
Abscess oral	1/358 (0.3%)		0/360 (0%)		0/360 (0%)
Abscess soft tissue	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Appendicitis	1/358 (0.3%)		0/360 (0%)		0/360 (0%)
Bronchitis	2/358 (0.6%)		0/360 (0%)		1/360 (0.3%)
Cellulitis	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Device related infection	1/358 (0.3%)		0/360 (0%)		0/360 (0%)
Endophthalmitis - Study eye	3/358 (0.8%)		3/360 (0.8%)		0/360 (0%)
Escherichia infection	0/358 (0%)		1/360 (0.3%)		0/360 (0%)
Escherichia urinary tract infection	0/358 (0%)		1/360 (0.3%)		0/360 (0%)
H1N1 influenza	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Herpes zoster	0/358 (0%)		1/360 (0.3%)		0/360 (0%)
Influenza	3/358 (0.8%)		0/360 (0%)		1/360 (0.3%)
Kidney infection	1/358 (0.3%)		1/360 (0.3%)		0/360 (0%)
Necrotising fasciitis	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Osteomyelitis	0/358 (0%)		0/360 (0%)		2/360 (0.6%)
Perineal cellulitis	0/358 (0%)		1/360 (0.3%)		0/360 (0%)
Pharyngitis	0/358 (0%)		1/360 (0.3%)		0/360 (0%)
Pneumonia	7/358 (2%)		10/360 (2.8%)		9/360 (2.5%)
Pneumonia bacterial	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Pyelonephritis	2/358 (0.6%)		0/360 (0%)		0/360 (0%)
Pyelonephritis acute	0/358 (0%)		1/360 (0.3%)		0/360 (0%)
Respiratory tract infection	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Sepsis	3/358 (0.8%)		4/360 (1.1%)		1/360 (0.3%)
Septic shock	0/358 (0%)		3/360 (0.8%)		0/360 (0%)
Urinary tract infection	4/358 (1.1%)		2/360 (0.6%)		2/360 (0.6%)
Injury, poisoning and procedural complications
Accidental overdose	1/358 (0.3%)		0/360 (0%)		0/360 (0%)
Cervical vertebral fracture	1/358 (0.3%)		0/360 (0%)		1/360 (0.3%)
Concussion	1/358 (0.3%)		0/360 (0%)		0/360 (0%)
Contusion	0/358 (0%)		2/360 (0.6%)		0/360 (0%)
Face injury	0/358 (0%)		1/360 (0.3%)		0/360 (0%)
Facial bones fracture - Fellow eye	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Fall	0/358 (0%)		2/360 (0.6%)		0/360 (0%)
Femoral neck fracture	1/358 (0.3%)		0/360 (0%)		1/360 (0.3%)
Femur fracture	0/358 (0%)		2/360 (0.6%)		4/360 (1.1%)
Forearm fracture	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Head injury	1/358 (0.3%)		0/360 (0%)		0/360 (0%)
Hip fracture	1/358 (0.3%)		0/360 (0%)		2/360 (0.6%)
Ilium fracture	1/358 (0.3%)		0/360 (0%)		0/360 (0%)
Incisional hernia	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Lower limb fracture	0/358 (0%)		1/360 (0.3%)		0/360 (0%)
Neck injury	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Overdose	0/358 (0%)		1/360 (0.3%)		0/360 (0%)
Pubis fracture	2/358 (0.6%)		0/360 (0%)		1/360 (0.3%)
Rib fracture	0/358 (0%)		1/360 (0.3%)		2/360 (0.6%)
Spinal fracture	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Sternal fracture	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Subarachnoid haemorrhage	1/358 (0.3%)		0/360 (0%)		0/360 (0%)
Subdural haematoma	1/358 (0.3%)		1/360 (0.3%)		3/360 (0.8%)
Toxicity to various agents	1/358 (0.3%)		0/360 (0%)		0/360 (0%)
Traumatic haematoma	0/358 (0%)		1/360 (0.3%)		1/360 (0.3%)
Ulna fracture	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Wrist fracture	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Investigations
Blood parathyroid hormone increased	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Blood pressure increased	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Platelet count decreased	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Metabolism and nutrition disorders
Dehydration	1/358 (0.3%)		0/360 (0%)		1/360 (0.3%)
Fluid retention	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Hyperkalaemia	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Hypervolaemia	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Hypoglycaemia	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Hyponatraemia	4/358 (1.1%)		2/360 (0.6%)		1/360 (0.3%)
Malnutrition	1/358 (0.3%)		0/360 (0%)		0/360 (0%)
Metabolic disorder	0/358 (0%)		1/360 (0.3%)		0/360 (0%)
Musculoskeletal and connective tissue disorders
Arthralgia	1/358 (0.3%)		0/360 (0%)		0/360 (0%)
Arthritis	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Back pain	0/358 (0%)		2/360 (0.6%)		1/360 (0.3%)
Chondrocalcinosis pyrophosphate	0/358 (0%)		1/360 (0.3%)		0/360 (0%)
Intervertebral disc protrusion	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Osteoarthritis	2/358 (0.6%)		1/360 (0.3%)		1/360 (0.3%)
Rotator cuff syndrome	0/358 (0%)		1/360 (0.3%)		0/360 (0%)
Soft tissue mass	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Spinal column stenosis	1/358 (0.3%)		0/360 (0%)		0/360 (0%)
Spondylolisthesis	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B-cell small lymphocytic lymphoma	0/358 (0%)		1/360 (0.3%)		0/360 (0%)
Bladder cancer	0/358 (0%)		1/360 (0.3%)		1/360 (0.3%)
Brain neoplasm	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Colon cancer	1/358 (0.3%)		0/360 (0%)		1/360 (0.3%)
Diffuse large B-cell lymphoma	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Gastric adenoma	0/358 (0%)		0/360 (0%)		2/360 (0.6%)
Gastric cancer	2/358 (0.6%)		1/360 (0.3%)		0/360 (0%)
Hepatic cancer	0/358 (0%)		1/360 (0.3%)		0/360 (0%)
Invasive ductal breast carcinoma	0/358 (0%)		2/360 (0.6%)		0/360 (0%)
Lung adenocarcinoma	0/358 (0%)		1/360 (0.3%)		1/360 (0.3%)
Lung cancer metastatic	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Lung carcinoma cell type unspecified stage IV	1/358 (0.3%)		1/360 (0.3%)		0/360 (0%)
Lung neoplasm malignant	1/358 (0.3%)		0/360 (0%)		1/360 (0.3%)
Lymphoma	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Malignant melanoma	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Mantle cell lymphoma recurrent	0/358 (0%)		1/360 (0.3%)		0/360 (0%)
Metastatic neoplasm	0/358 (0%)		1/360 (0.3%)		0/360 (0%)
Neoplasm malignant	1/358 (0.3%)		0/360 (0%)		2/360 (0.6%)
Non-small cell lung cancer	0/358 (0%)		2/360 (0.6%)		0/360 (0%)
Pancreatic carcinoma metastatic	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Prostate cancer	0/358 (0%)		1/360 (0.3%)		0/360 (0%)
Prostate cancer metastatic	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Rectal adenocarcinoma	1/358 (0.3%)		0/360 (0%)		0/360 (0%)
Renal cell carcinoma	1/358 (0.3%)		0/360 (0%)		0/360 (0%)
Squamous cell carcinoma of the hypopharynx	1/358 (0.3%)		0/360 (0%)		0/360 (0%)
Squamous cell carcinoma of the oral cavity	0/358 (0%)		1/360 (0.3%)		0/360 (0%)
Nervous system disorders
Amnesia	0/358 (0%)		1/360 (0.3%)		0/360 (0%)
Carotid artery occlusion	1/358 (0.3%)		0/360 (0%)		0/360 (0%)
Carotid artery stenosis	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Cerebral haemorrhage	1/358 (0.3%)		1/360 (0.3%)		0/360 (0%)
Cerebral infarction	1/358 (0.3%)		0/360 (0%)		0/360 (0%)
Cerebrovascular accident	3/358 (0.8%)		4/360 (1.1%)		3/360 (0.8%)
Dementia	2/358 (0.6%)		1/360 (0.3%)		1/360 (0.3%)
Encephalopathy	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Haemorrhagic cerebral infarction	1/358 (0.3%)		0/360 (0%)		0/360 (0%)
Headache	0/358 (0%)		1/360 (0.3%)		1/360 (0.3%)
Hypoaesthesia	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Intracranial aneurysm	1/358 (0.3%)		0/360 (0%)		0/360 (0%)
Ischaemic stroke	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Lacunar infarction	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Lumbar radiculopathy	1/358 (0.3%)		0/360 (0%)		0/360 (0%)
Lumbosacral radiculopathy	1/358 (0.3%)		0/360 (0%)		0/360 (0%)
Neurological decompensation	0/358 (0%)		1/360 (0.3%)		0/360 (0%)
Presyncope	0/358 (0%)		1/360 (0.3%)		0/360 (0%)
Sciatica	0/358 (0%)		1/360 (0.3%)		0/360 (0%)
Seizure	1/358 (0.3%)		0/360 (0%)		0/360 (0%)
Syncope	3/358 (0.8%)		2/360 (0.6%)		3/360 (0.8%)
Transient ischaemic attack	3/358 (0.8%)		1/360 (0.3%)		2/360 (0.6%)
VIth nerve paralysis - Fellow eye	0/358 (0%)		1/360 (0.3%)		0/360 (0%)
Product Issues
Device dislocation	1/358 (0.3%)		0/360 (0%)		0/360 (0%)
Device failure	1/358 (0.3%)		1/360 (0.3%)		0/360 (0%)
Psychiatric disorders
Anxiety	1/358 (0.3%)		0/360 (0%)		0/360 (0%)
Delirium	2/358 (0.6%)		0/360 (0%)		0/360 (0%)
Major depression	1/358 (0.3%)		0/360 (0%)		0/360 (0%)
Mental status changes	1/358 (0.3%)		0/360 (0%)		0/360 (0%)
Psychotic disorder	0/358 (0%)		1/360 (0.3%)		0/360 (0%)
Schizophrenia	1/358 (0.3%)		0/360 (0%)		0/360 (0%)
Suicide attempt	1/358 (0.3%)		0/360 (0%)		0/360 (0%)
Renal and urinary disorders
Acute kidney injury	0/358 (0%)		2/360 (0.6%)		0/360 (0%)
Chronic kidney disease	2/358 (0.6%)		0/360 (0%)		1/360 (0.3%)
Glomerulonephritis	0/358 (0%)		1/360 (0.3%)		0/360 (0%)
Haematuria	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Nephrolithiasis	1/358 (0.3%)		2/360 (0.6%)		2/360 (0.6%)
Renal cyst	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Renal failure	0/358 (0%)		1/360 (0.3%)		0/360 (0%)
Ureterolithiasis	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Reproductive system and breast disorders
Benign prostatic hyperplasia	0/358 (0%)		2/360 (0.6%)		1/360 (0.3%)
Prostatitis	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Respiratory, thoracic and mediastinal disorders
Acute respiratory failure	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Chronic obstructive pulmonary disease	1/358 (0.3%)		6/360 (1.7%)		4/360 (1.1%)
Dyspnoea	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Dyspnoea exertional	1/358 (0.3%)		0/360 (0%)		0/360 (0%)
Emphysema	0/358 (0%)		1/360 (0.3%)		0/360 (0%)
Mediastinal haematoma	1/358 (0.3%)		0/360 (0%)		0/360 (0%)
Pleural effusion	1/358 (0.3%)		0/360 (0%)		1/360 (0.3%)
Pneumothorax	0/358 (0%)		1/360 (0.3%)		1/360 (0.3%)
Pulmonary embolism	2/358 (0.6%)		0/360 (0%)		1/360 (0.3%)
Pulmonary hypertension	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Pulmonary oedema	1/358 (0.3%)		1/360 (0.3%)		2/360 (0.6%)
Respiratory failure	0/358 (0%)		2/360 (0.6%)		2/360 (0.6%)
Surgical and medical procedures
Hospitalisation	1/358 (0.3%)		0/360 (0%)		0/360 (0%)
Mass excision	0/358 (0%)		1/360 (0.3%)		0/360 (0%)
Vascular disorders
Aortic stenosis	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Arteriosclerosis	0/358 (0%)		1/360 (0.3%)		0/360 (0%)
Deep vein thrombosis	0/358 (0%)		1/360 (0.3%)		2/360 (0.6%)
Embolism venous	1/358 (0.3%)		0/360 (0%)		0/360 (0%)
Haematoma	0/358 (0%)		1/360 (0.3%)		1/360 (0.3%)
Hypertension	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Hypertensive crisis	1/358 (0.3%)		0/360 (0%)		0/360 (0%)
Inferior vena caval occlusion	1/358 (0.3%)		0/360 (0%)		0/360 (0%)
Intermittent claudication	0/358 (0%)		0/360 (0%)		1/360 (0.3%)
Peripheral arterial occlusive disease	1/358 (0.3%)		0/360 (0%)		0/360 (0%)
Peripheral ischaemia	1/358 (0.3%)		1/360 (0.3%)		0/360 (0%)
Other (Not Including Serious) Adverse Events
	Brolucizumab 3mg		Brolucizumab 6mg		Aflibercept 2mg
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	239/358 (66.8%)		228/360 (63.3%)		228/360 (63.3%)
Eye disorders
Cataract - Study eye	18/358 (5%)		19/360 (5.3%)		13/360 (3.6%)
Conjunctival haemorrhage - Study eye	39/358 (10.9%)		29/360 (8.1%)		32/360 (8.9%)
Dry eye - Fellow eye	16/358 (4.5%)		15/360 (4.2%)		24/360 (6.7%)
Dry eye - Study eye	20/358 (5.6%)		19/360 (5.3%)		26/360 (7.2%)
Eye pain - Study eye	28/358 (7.8%)		18/360 (5%)		21/360 (5.8%)
Neovascular age-related macular degeneration - Fellow eye	33/358 (9.2%)		32/360 (8.9%)		31/360 (8.6%)
Retinal haemorrhage - Study eye	14/358 (3.9%)		21/360 (5.8%)		20/360 (5.6%)
Visual acuity reduced - Study eye	34/358 (9.5%)		21/360 (5.8%)		27/360 (7.5%)
Vitreous detachment - Study eye	24/358 (6.7%)		19/360 (5.3%)		19/360 (5.3%)
Vitreous floaters - Study eye	26/358 (7.3%)		22/360 (6.1%)		16/360 (4.4%)
Infections and infestations
Bronchitis	12/358 (3.4%)		13/360 (3.6%)		21/360 (5.8%)
Influenza	15/358 (4.2%)		17/360 (4.7%)		20/360 (5.6%)
Nasopharyngitis	44/358 (12.3%)		38/360 (10.6%)		44/360 (12.2%)
Pneumonia	10/358 (2.8%)		23/360 (6.4%)		13/360 (3.6%)
Urinary tract infection	39/358 (10.9%)		26/360 (7.2%)		40/360 (11.1%)
Injury, poisoning and procedural complications
Fall	18/358 (5%)		8/360 (2.2%)		7/360 (1.9%)
Musculoskeletal and connective tissue disorders
Arthralgia	19/358 (5.3%)		15/360 (4.2%)		21/360 (5.8%)
Back pain	26/358 (7.3%)		13/360 (3.6%)		17/360 (4.7%)
Respiratory, thoracic and mediastinal disorders
Cough	20/358 (5.6%)		13/360 (3.6%)		17/360 (4.7%)
Vascular disorders
Hypertension	33/358 (9.2%)		25/360 (6.9%)		23/360 (6.4%)

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.